https://trial.medpath.com/news/03e834e8467875ef/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-financial-post 2024-11-21T11:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/46c2f0af76eca533/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-the-treatment-of-adults-with 2024-11-21T11:15:45+00:00 weekly 0.7 https://trial.medpath.com/news/3720d0520dd19ae9/zymeworks-inc-globenewswire-via-ritzau 2024-11-21T11:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/290840944395b1bd/weight-loss-drug-zepbound-may-lower-heart-failure-deaths 2024-11-21T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/a6901dd3d4c5b018/fda-approves-hs-treatment-bimzelx-pharmaceutical-executive 2024-11-21T11:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/bcb4a36ba9d5a62e/skin-patch-could-monitor-your-blood-pressure 2024-11-21T11:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/8ee103a93faee170/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T11:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/3be8cc0e4f0506b2/there-may-be-a-better-way-to-treat-hematoma-brain-bleeds 2024-11-21T11:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/51c8d179076c7bb1/fda-grants-u-s-approval-of-ziihera-r-zanidatamab-hrii-for-globenewswire 2024-11-21T11:02:15+00:00 weekly 0.7 https://trial.medpath.com/news/d470fe2115127b16/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-and-acute-lymphoblastic-leukemia 2024-11-21T10:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/cd7f94bfdb79ddd0/first-patient-treated-in-phase-i-ii-trial-in-acute-myeloid-globenewswire 2024-11-21T10:17:04+00:00 weekly 0.7 https://trial.medpath.com/news/07ae4ae857b3878b/puma-commences-phase-ii-trial-of-alisertib-for-breast-cancer-treatment-clinical-trials-arena 2024-11-21T10:04:03+00:00 weekly 0.7 https://trial.medpath.com/news/eb66ec26d135acd5/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T09:39:13+00:00 weekly 0.7 https://trial.medpath.com/news/b9e42cac0c942f17/precision-medicine-trials-for-epilepsy-proliferate-but-clin-neurology-today 2024-11-21T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/ed8c22dcc309359e/metastatic-triple-negative-breast-cancer-mtnbc-pipeline-globenewswire 2024-11-21T09:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/36a1a9f362fe3fa4/a-randomized-clinical-trial-evaluating-hydralazine-s-efficacy-in-early-stage-alzheimer-s-disease 2024-11-21T09:06:58+00:00 weekly 0.7 https://trial.medpath.com/news/fd6cd314fe2aeb8c/phase-3-win-for-protagonist-therapeutics-with-oral-plaque-psoriasis-drug 2024-11-21T08:55:43+00:00 weekly 0.7 https://trial.medpath.com/news/c222ccbdf53e6fbd/lupin-receives-fda-approval-for-generic-version-of-adderall-xr-express-pharma 2024-11-21T08:35:40+00:00 weekly 0.7 https://trial.medpath.com/news/888732a46b578b4c/mural-oncology-announces-publication-highlighting-promising-clinical-antitumor-activity 2024-11-21T08:17:16+00:00 weekly 0.7 https://trial.medpath.com/news/00b0cb6beb864b5c/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/2c6f67178a81fc54/omics-based-clinical-trials-market-size-to-hit-usd-70-92-billion-by-2034-biospace 2024-11-21T08:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/672ecbccd965319f/china-dominates-apac-s-emergence-as-global-trials-hub-citeline 2024-11-21T08:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/81678859771518b8/hanmi-pharm-advances-launch-of-obesity-drug-efpeglenatide-to-late-2026-kbr 2024-11-21T07:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/1bad53bc82d17af9/hanmi-pharma-to-move-up-launch-of-anti-obesity-drug-ked-global 2024-11-21T07:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/2ab221e75a42292a/inxmed-fak-inhibitor-ifebemtinib-received-breakthrough-therapy-designation-by-morningstar 2024-11-21T07:44:42+00:00 weekly 0.7 https://trial.medpath.com/news/7a0fee5b60a3b5b6/elon-musk-s-neuralink-cleared-to-start-brain-chip-trial-in-canada-bnn-bloomberg 2024-11-21T06:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/f3d0568fe13479ed/biomind-labs-welcomes-u-s-policy-shift-as-a-historic-milestone-for-psychedelic-therapies 2024-11-21T06:44:57+00:00 weekly 0.7 https://trial.medpath.com/news/e943c697fa8fa249/liquid-biopsy-summit-2025-to-showcase-latest-advances-in-cancer-detection-and-monitoring 2024-11-21T06:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/b7330e916f77ede7/elon-musk-s-neuralink-gets-green-light-to-launch-brain-chip-trial-in-canada-benzinga 2024-11-21T05:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/d2db6ee83a45e61b/vir-biotechnology-hold-rating-amidst-promising-hdv-study-results-and-future-hbv-developments 2024-11-21T05:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/ba053d18c79c6c04/elon-musk-s-neuralink-receives-canadian-approval-for-brain-chip-trial-deccan-herald 2024-11-21T05:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/a7aba5e4550730af/hanmi-pharmaceutical-accelerates-launch-of-obesity-drug-to-2nd-half-of-2026 2024-11-21T05:19:40+00:00 weekly 0.7 https://trial.medpath.com/news/337e1b7b134c907b/marianna-fontana-md-phd-nex-z-shows-promise-in-attr-cm-phase-1-trial-hcplive 2024-11-21T05:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/71bb9d1299341a23/clinical-trials-help-grandfather-with-incurable-prostate-cancer-turn-back-the-clock-fox-47 2024-11-21T04:47:07+00:00 weekly 0.7 https://trial.medpath.com/news/afcbce0a8775bb3b/india-launches-first-indigenous-antibiotic-nafithromycin-to-combat-drug-resistance 2024-11-21T04:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/d0069e7b384e5834/gsk-drug-for-rare-disease-related-itch-meets-goal-in-phase-iii-study-yahoo-finance 2024-11-21T04:18:58+00:00 weekly 0.7 https://trial.medpath.com/news/7dd25e564298a93e/georg-schett-md-on-exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-21T04:10:32+00:00 weekly 0.7 https://trial.medpath.com/news/e086586e78e37208/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved-newswise 2024-11-21T04:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/38365bc7f50df842/city-of-hope-revolutionizes-cancer-care-through-patient-centered-approach-and-expanded-access 2024-11-21T04:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/42054c8b1b194c4d/jazz-pharmaceuticals-announces-fda-approval-of-ziihera-in-btc-markets-insider 2024-11-21T04:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/491bca069fee73b3/greater-bay-area-international-clinical-trial-institute-officially-opened-in-hong-kong-park-of 2024-11-21T03:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/bf98419a982bb6b0/ocugen-announces-european-medicines-agency-grants-orphan-medicinal-the-globe-and-mail 2024-11-21T03:16:45+00:00 weekly 0.7 https://trial.medpath.com/news/1aa5121f4af6260b/digital-experience-platforms-revolutionize-pharmaceutical-claims-management-and-hcp-engagement 2024-11-21T02:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/786e7fa931841233/dr-pobel-on-the-prognostic-value-of-phenotypic-and-genomic-characterization-in-de-novo-mcspc 2024-11-21T02:03:41+00:00 weekly 0.7 https://trial.medpath.com/news/30de597b98c68c0c/biktarvy-shows-long-term-efficacy-and-safety-in-hiv-hbv-coinfection-after-three-years 2024-11-21T01:50:56+00:00 weekly 0.7 https://trial.medpath.com/news/48b6eb15c5c69bec/fda-oks-zanidatamab-injection-for-metastatic-her2-biliary-tract-cancer 2024-11-21T01:47:58+00:00 weekly 0.7 https://trial.medpath.com/news/7a156b7f51eff7e7/fda-approves-zanidatamab-for-previously-treated-unresectable-or-metastatic-her2-onclive 2024-11-21T01:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/459b9060f2ba830e/biomind-labs-hails-u-s-support-for-psychedelic-therapies-tipranks-com 2024-11-21T00:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/1df132d475851d4b/fda-approves-long-awaited-clinical-trial-of-smoked-marijuana-to-treat-ptsd-in-veterans 2024-11-21T00:45:52+00:00 weekly 0.7 https://trial.medpath.com/news/f16507d1df97d760/jazz-pharma-s-ziihera-wins-fda-approval-with-52-response-rate-in-cancer-trial 2024-11-21T00:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/5f5f43f6ade5cc51/fda-committees-vote-to-dismiss-clozapine-rems-psychiatric-times 2024-11-21T00:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/df12f8dccee53422/vir-biotechnology-s-promising-advancements-in-hepatitis-treatments-justify-buy-rating 2024-11-21T00:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/4f5ee56d3586a3a5/hrx-215-drug-targets-indications-patents 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/265a8821da980c05/pila-pharma-announces-initiation-of-study-in 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/06b3faa987048115/conduit-pharmaceuticals-secures-japanese-patent-for-azd1656-glucokinase-activator-targeting-autoimmune-disorders 2024-11-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/8e55b86720f7dec1/lisaftoclax-nda-accepted-for-review-in-china-for-relapsed-refractory-cll-sll-onclive 2024-11-20T23:58:42+00:00 weekly 0.7 https://trial.medpath.com/news/250a22e11b6ad80c/new-phase-3-data-of-jnj-2113-for-plaque-psoriasis-in-patients-aged-12-years-older 2024-11-20T23:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/0a214c6bc5716ba9/biomind-labs-bmnd08-achieves-100-efficacy-in-phase-ii-depression-trial-bmndf-stock-news 2024-11-20T23:47:16+00:00 weekly 0.7 https://trial.medpath.com/news/b4ad28cd73488161/newamsterdam-s-obicetrapib-combo-nails-phase-iii-ldl-c-endpoints-bioworld 2024-11-20T23:46:15+00:00 weekly 0.7 https://trial.medpath.com/news/caedd44deeb521fe/sage-shuts-down-huntington-s-program-after-phase-ii-failure-bioworld 2024-11-20T23:46:08+00:00 weekly 0.7 https://trial.medpath.com/news/4814883b2d35ca4c/osimertinib-approaches-eu-approval-in-locally-advanced-egfr-nsclc-after-chemoradiation 2024-11-20T23:45:38+00:00 weekly 0.7 https://trial.medpath.com/news/23a005d9676c6d27/corvent-wins-fda-clearance-for-respond-critical-care-ventilator-massdevice 2024-11-20T22:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/443ce37ec9f1f601/sage-s-pipeline-prospects-narrow-further-as-dalzanemdor-fails-in-huntington-s-citeline 2024-11-20T22:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/52d43b8afddbc2e8/fda-approves-clinical-trials-for-medical-cannabis-to-treat-ptsd-in-military-veterans 2024-11-20T22:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/41971a7e0a48cdae/new-treatment-combination-for-subdural-hematoma-reduces-risk-of-recurrence 2024-11-20T22:35:42+00:00 weekly 0.7 https://trial.medpath.com/news/ed1471633128041f/cardiol-therapeutics-cardiolrx-gains-buy-rating-on-positive-phase-2-results-and-strong 2024-11-20T22:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/881fa26f1ae59f08/fda-clears-ai-screening-tool-for-cardiac-amyloidosis-cardiovascular-business 2024-11-20T22:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/c5dd2fccb70df2b1/target-switch-and-high-risk-cohorts-support-talquetamab-use-in-rrmm 2024-11-20T22:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/006433e143b3d2e5/the-fda-approves-labeling-update-for-sandoz-in-the-treatment-of-b-cell-cll-cure-today 2024-11-20T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/c59d2d7a0a1e612c/vir-biotechnology-poised-for-outperformance-keeps-buy-rating-on-pipeline-potential 2024-11-20T21:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/65f8579b9dfabe8a/fda-clears-phase-2-trial-of-cannabis-in-ptsd-managed-healthcare-executive 2024-11-20T21:28:38+00:00 weekly 0.7 https://trial.medpath.com/news/b93f1967f5390916/a-watershed-moment-glp-1-drug-succeeds-in-late-stage-mash-trial-medpage-today 2024-11-20T21:24:19+00:00 weekly 0.7 https://trial.medpath.com/news/82aa977d8ea2e597/european-commission-approves-aflibercept-biosimilar-opuviz-previously-sb15-from 2024-11-20T21:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/a7b81099fa5d2f21/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/86aba02b5dd57c82/organovo-presents-clinical-data-of-fxr314-in-phase-2-mash-in-an-oral-yahoo-finance 2024-11-20T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/08b30e444d1d3e76/nurix-s-cancer-drug-nx-5948-secures-ema-prime-status-for-advanced-leukemia-treatment 2024-11-20T21:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/ce8f57ba89663e8d/around-the-helix-cell-and-gene-therapy-company-updates-november-20-2024 2024-11-20T21:05:54+00:00 weekly 0.7 https://trial.medpath.com/news/7ae08c82322d5dcd/nurix-therapeutics-receives-prime-designation-from-the-european-medicines-agency-for 2024-11-20T21:03:19+00:00 weekly 0.7 https://trial.medpath.com/news/3372928f595bc95e/fda-approves-bimzelx-for-adults-with-moderate-to-severe-hidradenitis-suppurativa-healio 2024-11-20T20:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/6c862f4565f62f26/fda-fast-tracks-ale-p02-for-cldn1-poisitive-solid-cancers-oncology-nursing-news 2024-11-20T20:08:23+00:00 weekly 0.7 https://trial.medpath.com/news/5843e9912745145f/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T20:04:48+00:00 weekly 0.7 https://trial.medpath.com/news/83443a4c72b069e4/first-mpox-vaccine-for-children-approved-by-who-to-fight-virus-outbreak-euronews 2024-11-20T19:57:14+00:00 weekly 0.7 https://trial.medpath.com/news/87ed494f91b8ee31/biotech-initiates-phase-iii-trial-for-heart-disease-drug-the-streetwise-reports 2024-11-20T19:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/bd4224efb223d4ac/fda-approves-bimzelx-for-inflammatory-skin-disease-managed-healthcare-executive 2024-11-20T19:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/8a96897dbb0094b8/eu-approval-recommended-for-repotrectinib-in-ros1-nsclc-ntrk-solid-tumors 2024-11-20T19:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/e366e3859773ea6e/fda-approves-ucb-s-psoriasis-drug-for-expanded-use-in-painful-inflammatory-skin-disease 2024-11-20T19:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/c9a6af5f7fa479ab/sylvester-duo-advances-research-on-aggressive-rare-gynecologic-cancers-inventum 2024-11-20T18:47:57+00:00 weekly 0.7 https://trial.medpath.com/news/27c9fb365fc703db/breakthrough-molecule-heals-gut-blocks-tumors-mirage-news 2024-11-20T18:43:11+00:00 weekly 0.7 https://trial.medpath.com/news/e3b98f094b85dc22/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:42:47+00:00 weekly 0.7 https://trial.medpath.com/news/e9e161059cc07fe0/positive-phase-iii-results-for-linerixibat-in-cholestatic-pruritus-treatment-for-pbc-patients 2024-11-20T18:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/c2a6ca8093c7ca0b/brain-breakthrough-4-common-heart-drugs-may-also-lower-dementia-risk-study-finds 2024-11-20T18:18:02+00:00 weekly 0.7 https://trial.medpath.com/news/e0fc2d30ac1517cb/the-dust-has-settled-sage-s-dalzanemdor-won-t-advance-for-cognitive-impairment-hdbuzz 2024-11-20T18:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/0b4791fda4aa93b9/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T17:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/0fdc9936b6d019fa/fda-approves-omron-ai-powered-afib-detection-in-blood-pressure-monitors 2024-11-20T17:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/d7febc733956d848/puma-biotechnology-announces-initiation-of-alisca-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T17:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/44d6d68f99a94573/phase-3-trials-of-c3g-therapies-docwire-news 2024-11-20T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/7a35830620c720b3/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-20T17:24:10+00:00 weekly 0.7 https://trial.medpath.com/news/1a6e4566110b2fa9/zerlasiran-achieves-significant-sustained-reduction-in-lipoprotein-a-levels-with-infrequent-dosing 2024-11-20T17:15:50+00:00 weekly 0.7 https://trial.medpath.com/news/212a75975b590bc8/the-influence-of-pd-1-inhibitor-label-restrictions-on-future-studies 2024-11-20T17:15:30+00:00 weekly 0.7 https://trial.medpath.com/news/269ea3de657981bb/neurovoices-charbel-moussa-phd-mbbs-on-therapeutic-potential-of-nilotinib-in 2024-11-20T17:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/cd7d5801b5d594b7/sage-s-string-of-research-failures-continues-biopharma-dive 2024-11-20T17:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/de577ed45d0e1109/levi-04-improved-outcomes-in-knee-osteoarthritis-compared-with-placebo-hcplive 2024-11-20T16:57:57+00:00 weekly 0.7 https://trial.medpath.com/news/73f1dfe05cedefa3/pbc-treatment-livdelzi-shows-benefits-for-2-5-years-in-phase-3-trial 2024-11-20T16:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/09803c4bfb22d37c/fda-approves-new-drug-labeling-for-fludarabine-phosphate-in-cll-onclive 2024-11-20T16:40:42+00:00 weekly 0.7 https://trial.medpath.com/news/5ee26f5b9a87d04e/new-eu-approvals-citeline 2024-11-20T16:40:25+00:00 weekly 0.7 https://trial.medpath.com/news/a4c335a3481d5405/pfizer-s-hympavzi-for-hemophilia-a-or-b-receives-eu-approval-outsourcing-pharma-com 2024-11-20T16:40:19+00:00 weekly 0.7 https://trial.medpath.com/news/9ad128cb552d575f/eupraxia-s-diffuspheretm-technology-demonstrates-targeted-drug-release-while 2024-11-20T16:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/3284fa8315988207/taho-pharma-begins-patient-dosing-in-us-phase-iii-trial-of-antithrombotic-oral-dissolving 2024-11-20T16:30:45+00:00 weekly 0.7 https://trial.medpath.com/news/e0d47c5661b8aa05/an-inhaled-pi3kd-inhibitor-disclosed-by-chiesi-farmaceutici-suggests-the-target-is-unsuitable-for-managing-copd 2024-11-20T16:13:16+00:00 weekly 0.7 https://trial.medpath.com/news/edd01010b115c747/medtronic-begins-multicenter-study-to-address-health-disparities-in-structural-heart-disease-care 2024-11-20T16:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/339dd94ef16aa7db/jacksonville-university-partners-with-brooks-rehabilitation-and-other-universities-to-develop 2024-11-20T16:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/c141c3e92d1f27ce/alpha-biopharma-received-nmpa-approval-for-zorifertinib-tablets-zorifer-r-the-world-s-first 2024-11-20T16:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/0c55cc94f786db67/reused-pacemakers-are-good-as-new-kratom-still-readily-available-nih-ai-matches 2024-11-20T16:08:03+00:00 weekly 0.7 https://trial.medpath.com/news/88a9845a2a9b1447/fda-updates-fludarabine-labeling-under-project-renewal-initiative-targeted-oncology 2024-11-20T16:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/06d19c9517cb2749/holding-pattern-awaiting-clarity-on-vir-biotechnology-s-potential-amid-promising-trials-and 2024-11-20T16:04:47+00:00 weekly 0.7 https://trial.medpath.com/news/2936c5f1b6ac9492/regenxbio-gene-therapy-advances-to-pivotal-trials-in-dmd-inside-precision-medicine 2024-11-20T15:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/36f2e1631b4d1803/research-finds-dlbcl-patients-starting-treatment-immediately-face-worse-outcomes 2024-11-20T15:56:21+00:00 weekly 0.7 https://trial.medpath.com/news/97ed9a07966b6e25/fda-clears-ai-powered-ultrasound-software-for-cardiac-amyloidosis-detection 2024-11-20T15:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/f40860eb89712bc8/dr-forsyth-on-a-phase-1-study-evaluating-intrathecal-cdc1s-in-leptomeningeal-disease-onclive 2024-11-20T15:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/49db9221db41db65/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T15:39:51+00:00 weekly 0.7 https://trial.medpath.com/news/f7d1c17fe074ff80/ezh2-enzyme-linked-to-drug-resistance-and-tumor-growth-in-prostate-cancer 2024-11-20T15:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/15b6f93e50096461/fda-approves-bimekizumab-in-hidradenitis-suppurativa 2024-11-20T15:20:52+00:00 weekly 0.7 https://trial.medpath.com/news/2f62921222cba59f/medtronic-wins-fda-nod-for-new-inpen-app-to-support-launch-with-simplera-cgm 2024-11-20T15:01:59+00:00 weekly 0.7 https://trial.medpath.com/news/2df436b88f774e2c/eu-regulators-said-no-to-alzheimer-s-drug-leqembi-now-they-re-saying-yes 2024-11-20T14:59:09+00:00 weekly 0.7 https://trial.medpath.com/news/9d3ee47b84d7b356/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing-biospace 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/1a0b5e65b3469268/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:54:49+00:00 weekly 0.7 https://trial.medpath.com/news/d2d0c5cadf93d493/capricor-therapeutics-granted-orphan-drug-and-atmp-status-for-deramiocel-by-european 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/cfba1dafcf6d6ff4/newamsterdam-pharma-announces-positive-topline-data-from-pivotal-phase-3-tandem 2024-11-20T14:54:48+00:00 weekly 0.7 https://trial.medpath.com/news/b885e5d11ded6230/fda-grants-rare-pediatric-disease-fast-track-designations-to-stargardt-disease-therapy 2024-11-20T14:43:03+00:00 weekly 0.7 https://trial.medpath.com/news/e656203d24668b3a/capricor-s-deramiocel-gains-key-ema-designations-for-dmd-investing-com 2024-11-20T14:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/3bce0aa4d0591fc0/sage-scraps-huntington-s-hopeful-after-disappointing-phase-ii-data-biospace 2024-11-20T14:31:32+00:00 weekly 0.7 https://trial.medpath.com/news/8e0ccf08ed70834e/fda-approves-bimekizumab-for-adults-with-hidradenitis-suppurativa-hcplive 2024-11-20T14:23:10+00:00 weekly 0.7 https://trial.medpath.com/news/9a6e19a46bea8cf9/fda-approves-bimekizumab-bkzx-as-treatment-for-hidradenitis-suppurativa 2024-11-20T14:20:35+00:00 weekly 0.7 https://trial.medpath.com/news/3a344ccb795ffa99/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-ongoing 2024-11-20T14:14:10+00:00 weekly 0.7 https://trial.medpath.com/news/493305a5aa1fb1e1/medtronic-says-fda-clears-inpen-app-clearing-path-for-glucose-monitoring-system-launch 2024-11-20T14:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/4275677ea31a49c4/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:14:02+00:00 weekly 0.7 https://trial.medpath.com/news/5d2b902aaebdc485/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:13:13+00:00 weekly 0.7 https://trial.medpath.com/news/0b0265b93127b6ea/puma-biotechnology-initiates-alisertib-in-cancer-trial-tipranks-com 2024-11-20T14:13:07+00:00 weekly 0.7 https://trial.medpath.com/news/153b47efbdaa9eaf/towards-a-precision-approach-to-anesthetic-analgesic-immunomodulation-in-cancer 2024-11-20T14:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/79bc4122e6655a7d/renovorx-announces-nhci-is-enrolling-patients-for-phase-iii-tiger-pac-trial-tipranks 2024-11-20T14:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/e87985cab94e32dc/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/12cf68e893ddf3e1/study-unveils-key-strategies-against-drug-resistant-prostate-cancer-newsroom 2024-11-20T14:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/b603a94d645be898/ucb-s-bimzelx-approved-by-fda-for-treatment-of-adults-with-hidradenitis-suppurativa 2024-11-20T14:04:56+00:00 weekly 0.7 https://trial.medpath.com/news/1991881f7b4d78ca/capricor-therapeutics-granted-orphan-drug-and-atmp-status-globenewswire 2024-11-20T14:04:54+00:00 weekly 0.7 https://trial.medpath.com/news/f0206ced60fa50d6/koelis-announces-the-first-interim-results-of-the-violette-globenewswire 2024-11-20T14:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/cfd7d76a3e7f917c/ultromics-obtains-breakthrough-device-fda-clearance-for-its-cardiac-amyloidosis-screening 2024-11-20T14:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/9ddc00b70388b6b0/puma-biotech-launches-phase-2-trial-for-advanced-breast-cancer-treatment-stock-titan 2024-11-20T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/409a12e97801a304/renovorx-expands-phase-iii-pancreatic-cancer-trial-with-major-cancer-institute-partnership 2024-11-20T14:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/7c8b55c97413371d/ema-s-strategy-for-speeding-up-drug-approvals-in-the-eu-pharmaphorum 2024-11-20T14:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/4dc18feef398316d/2024-a-breakthrough-year-for-hypoparathyroidism-treatment-labiotech 2024-11-20T14:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/7e1f6a30e05f3a4e/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/50491b830fb218d0/new-details-on-a-risky-medical-device-show-need-for-more-fda-transparency-researchers-say 2024-11-20T14:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/47c41f6391daf5cd/puma-biotechnology-announces-initiation-of-aliscatm-breast1-phase-ii-trial-of-alisertib-in 2024-11-20T14:00:27+00:00 weekly 0.7 https://trial.medpath.com/news/456c71516d9080f4/biovie-to-present-design-of-planned-phase-2-study-of-bezisterim-for-the-treatment-of-long 2024-11-20T13:55:06+00:00 weekly 0.7 https://trial.medpath.com/news/c8512f148589145f/northwell-health-cancer-institute-launches-patient-enrollment-in-renovorx-s-globenewswire 2024-11-20T13:47:36+00:00 weekly 0.7 https://trial.medpath.com/news/768ae41f608f51da/precision-for-medicine-and-agena-bioscience-announce-strategic-partnership-yahoo-finance 2024-11-20T13:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/811de84fac1629c0/medtronic-secures-fda-clearance-for-revolutionary-smart-insulin-dosing-system-mdt-stock-news 2024-11-20T13:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/fa7fdb7ffba4c438/organovo-reports-positive-phase-2-results-for-liver-drug-fxr314-investing-com 2024-11-20T13:39:23+00:00 weekly 0.7 https://trial.medpath.com/news/1db3dff51ec634b1/sage-therapeutics-announces-topline-results-from-the-phase-2-dimension-study-of-biospace 2024-11-20T13:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/cc5ceb4a90c61548/eli-lilly-obesity-drug-reduces-risk-of-heart-failure-phase-iii-study-finds-medwatch 2024-11-20T13:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/c2025d323f15921b/medtronic-receives-fda-clearance-for-new-inpentm-app-paving-the-way-for-its-smart-mdi 2024-11-20T13:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/3db150236fecd7cf/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/a0484172ff29717d/painreform-announces-initial-topline-data-for-prf-110-phase-3-clinical-trial 2024-11-20T13:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/4736c210a4f72641/praxis-precision-medicines-provides-corporate-update-and-reports-fourth-quarter-and-full 2024-11-20T13:33:26+00:00 weekly 0.7 https://trial.medpath.com/news/e3e8caff56d66320/ocugen-receives-orphan-medicinal-product-designation-from-ema-for-ocu410st 2024-11-20T13:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/99a6e11ec0b777ec/ucb-reports-fda-approval-of-bimzelx-in-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T13:26:24+00:00 weekly 0.7 https://trial.medpath.com/news/f3a38526d163349a/november-20-2022-in-this-week-s-pct-grand-rounds-the-helix-pragmatic-trial-in 2024-11-20T13:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/02d5310239cb77bf/fda-approves-bimekizumab-for-adults-with-moderate-to-severe-hs-dermatology-times 2024-11-20T13:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/582323ac4ffe574a/novotech-releases-report-on-global-bladder-cancer-clinical-trials-offering-insights-for 2024-11-20T13:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/e4962001a853c72d/phase-3-trial-data-inform-advancements-in-targeted-therapy-for-gastric-gej-cancers 2024-11-20T13:15:37+00:00 weekly 0.7 https://trial.medpath.com/news/3cd748be2f35169e/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300 2024-11-20T13:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/f4e5076ae93a1e01/pharmanovia-licenses-lindis-catumaxomab-for-malignant-ascites-treatment 2024-11-20T13:11:37+00:00 weekly 0.7 https://trial.medpath.com/news/4183bad395f91239/mira-reveals-innovative-phase-i-iia-protocol-design-and-selection-of-clinical-trial-site 2024-11-20T13:06:59+00:00 weekly 0.7 https://trial.medpath.com/news/1c23743141b52a5e/transitioning-active-clinical-trials-under-eu-ctr-contract-pharma 2024-11-20T13:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/312f1cc49ce46e59/new-way-to-run-clinical-trials-within-general-practice-reaches-1000-nhs-patients-recruited 2024-11-20T12:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/115a0a4cdbcaae2f/ucb-s-bimzelx-granted-fda-approval-to-treat-hidradenitis-suppurativa-in-adults-pmlive 2024-11-20T12:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/67e79d37de45baeb/ocugen-announces-european-medicines-agency-grants-orphan-globenewswire 2024-11-20T12:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/f33053505b992bff/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:38:30+00:00 weekly 0.7 https://trial.medpath.com/news/6f690dfbab763f18/pfizer-bags-eu-okay-for-haemophilia-drug-hympavzi-pharmaphorum 2024-11-20T12:32:58+00:00 weekly 0.7 https://trial.medpath.com/news/6cf5e40a72e85697/ocugen-s-eye-disease-drug-shows-84-lesion-reduction-receives-ema-orphan-status 2024-11-20T12:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/db77bde6fc43c092/a-randomized-clinical-trial-of-intranasal-dexmedetomidine-versus-inhaled-nitrous-oxide-for 2024-11-20T12:25:25+00:00 weekly 0.7 https://trial.medpath.com/news/949bf60ba627322e/pfizer-gets-european-approval-of-hympavzi-hemophilia-drug-morningstar 2024-11-20T12:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/65948850c0699efa/melt-pharma-s-melt-300-shows-breakthrough-results-in-phase-3-sedation-trial 2024-11-20T12:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/7a2218d16c1cf83d/melt-pharmaceuticals-reports-positive-phase-3-topline-efficacy-results-for-melt-300-its 2024-11-20T12:17:47+00:00 weekly 0.7 https://trial.medpath.com/news/870d006dbad98325/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T12:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/35785ce41c9830d4/gigagen-commences-phase-i-clinical-trial-of-giga-2339-for-hepatitis-b-treatment 2024-11-20T12:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/cd4cc4954097121a/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a 2024-11-20T12:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/1aa7b5cf3c4c8085/injecting-hope-clinuvel-eyes-higher-scenesse-usage-in-europe-sharecafe 2024-11-20T12:01:41+00:00 weekly 0.7 https://trial.medpath.com/news/b617f48be703fb27/sol-gel-announces-180-day-extension-to-regain-compliance-globenewswire 2024-11-20T12:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/613253f8037b251a/personalized-medicine-biomarkers-market-set-to-reach-79-26-billion-by-2034-driven-by-precision-oncology-and-ai 2024-11-20T11:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/c8c0bb327fa74050/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-pharmabiz-com 2024-11-20T11:32:30+00:00 weekly 0.7 https://trial.medpath.com/news/0714a078606f3276/aha-2024-phase-iii-brooklyn-trial-safety-and-efficacy-of-obicetrapib-in-hefh-patients 2024-11-20T11:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/59077420228cedd1/rozebalamin-for-injection-25mg-mecobalamin-for-amyotrophic-lateral-sclerosis-launched-in-japan 2024-11-20T10:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/6bd052db0f681ab4/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab 2024-11-20T10:49:17+00:00 weekly 0.7 https://trial.medpath.com/news/c42fa866611a69c8/sen-jam-pharma-launches-phase-ii-trial-of-hangover-prevention-treatment-msn 2024-11-20T10:41:27+00:00 weekly 0.7 https://trial.medpath.com/news/61bf8e9f233230a3/msd-reports-topline-outcomes-from-phase-iii-nsclc-trial-of-pembrolizumab-yahoo 2024-11-20T10:33:43+00:00 weekly 0.7 https://trial.medpath.com/news/67bd6eb9ba771712/novo-nordisk-s-semaglutide-tops-madrigal-s-rezdiffra-in-nash-citeline 2024-11-20T10:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/a9ea3520b4974944/spyglass-pharma-completes-enrollment-in-phase-i-ii-study-of-its-promising-long-term 2024-11-20T09:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/44063b0a4a1830dd/ucb-gets-fda-approval-for-bimzelx-for-hidradenitis-suppurativa-bloomberg-law-news 2024-11-20T09:21:46+00:00 weekly 0.7 https://trial.medpath.com/news/05b28e892aa1153c/sen-jam-s-first-in-class-fda-regulated-hangover-cure-enters-phase-2-trials 2024-11-20T09:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/1653629a2a7f8912/lupus-therapeutics-statement-on-phase-3-phoenycs-go-positive-data-in-moderate-to 2024-11-20T08:57:22+00:00 weekly 0.7 https://trial.medpath.com/news/31d1983a22567c5d/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-20T08:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/f2621a9683fcaec2/ongoing-and-planned-research-build-on-prior-advancements-in-er-her2-breast-cancer 2024-11-20T08:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/1b2bfa5f1c3c6531/fda-shares-additional-draft-guidance-on-cgts-clinical-trials-arena 2024-11-20T08:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/afd9659847bb97e5/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T08:03:29+00:00 weekly 0.7 https://trial.medpath.com/news/e94ce36930c12f67/incyte-sinks-on-setback-for-drugs-acquired-in-750m-buyout-biopharma-dive 2024-11-20T07:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/438c9f9b0b2c815d/lupin-receives-us-fda-approval-for-generic-adderall-xr-extended-release-capsules 2024-11-20T07:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/a0e1649646567b8d/incyte-s-750m-escient-bet-flops-as-skin-disease-assets-stumble-biospace 2024-11-20T06:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/77275d4c173213cd/menstrual-regulation-and-promoting-pregnancy-acupuncture-method-based-jmdh 2024-11-20T06:41:29+00:00 weekly 0.7 https://trial.medpath.com/news/d23a09d11ea22ecc/ucb-receives-u-s-fda-approval-for-bimzelx-r-bimekizumab-bkzx-as-the-first-il-17a-and 2024-11-20T06:01:25+00:00 weekly 0.7 https://trial.medpath.com/news/d13e666a6801c197/ai-drug-repurposing-tool-offers-suggestions-based-on-disease-networks 2024-11-20T06:00:05+00:00 weekly 0.7 https://trial.medpath.com/news/50d97a0cc26e1f67/clinical-trial-access-and-value-critical-analysis-reveals-geographic-disparities-and-questions-patient-benefits 2024-11-20T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6ebb2a83f2fcb8a4/successful-completion-of-planned-idmc-review-of-action3-phase-3-fsgs 2024-11-20T05:49:04+00:00 weekly 0.7 https://trial.medpath.com/news/d0d7016097532fd2/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-pipelinereview 2024-11-20T05:46:05+00:00 weekly 0.7 https://trial.medpath.com/news/f6b4533aeaea2008/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase 2024-11-20T05:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/250cdd9bca7e8c3b/lupin-receives-usfda-approval-for-mixed-salts-of-a-single-entity-amphetamine-er-capsules 2024-11-20T05:24:32+00:00 weekly 0.7 https://trial.medpath.com/news/970c4445aa7298ac/pharma-companies-boost-medical-affairs-investment-to-enhance-clinical-trial-efficiency 2024-11-20T05:17:48+00:00 weekly 0.7 https://trial.medpath.com/news/ce3b0a72e2e0e62c/gsk-announces-positive-results-from-glisten-phase-iii-trial-of-linerixibat-in-adults-with 2024-11-20T04:31:01+00:00 weekly 0.7 https://trial.medpath.com/news/b7c6c91ef73f211a/cybin-s-breakthrough-psychedelic-depression-drug-cyb003-sustains-12-month-symptom 2024-11-20T03:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/a9f382ffc0906a51/gsk-plots-regulatory-filings-for-pbc-itch-after-positive-phase-3-readout-endpoints-news 2024-11-20T03:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/e683930e8cdd33ed/fda-grants-accelerated-approval-to-ziihera-zanidatamab-hrii-for-the-treatment-of-her2-positive-biliary-tract-cancer 2024-11-20T02:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/4a553c5e995d181d/bimekizumab-data-from-acr-conference-highlights-sustained-efficacy-in-psoriatic-arthritis 2024-11-20T02:05:17+00:00 weekly 0.7 https://trial.medpath.com/news/b81e62c37c5883f0/samsung-bioepis-wins-european-approval-for-ophthalmic-biosimilar-opuviz-maeilgyeongje 2024-11-20T02:03:25+00:00 weekly 0.7 https://trial.medpath.com/news/ea842c4ee9cd7b7c/neurogene-reports-serious-adverse-event-in-phase-1-2-rett-study-of-gene-therapy-ngn-401 2024-11-20T02:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/8d47bbb08509d151/breakthrough-therapy-shows-promising-long-term-results-for-depression-the-streetwise-reports 2024-11-20T01:26:02+00:00 weekly 0.7 https://trial.medpath.com/news/8e9b57780adb28b2/epigenic-therapeutics-to-enter-clinical-development-of-epi-003-a-first-in-class-epigenetic 2024-11-20T01:15:32+00:00 weekly 0.7 https://trial.medpath.com/news/da69ff2fb6403a78/ucb-receives-u-s-fda-approval-for-bimzelx-bimekizumab-bkzx-as-the-first-il-17a-and-il-17f-inhibitor-for-adults-with-moderate-to-severe-hidradenitis-suppurativa 2024-11-20T01:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/1456fdd245a15c69/cardio-drugs-and-dementia-fampridine-and-working-memory-alzheimer-s-and-cancer 2024-11-20T00:45:54+00:00 weekly 0.7 https://trial.medpath.com/news/da471761494959ef/cannabidiol-cbd-for-the-management-of-cannabis-withdrawal-unsw-sydney 2024-11-20T00:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/cded672b5e4b72e8/essence-phase-3-trial-results-demonstrating-statistically-significant-and-superior-biospace 2024-11-20T00:37:22+00:00 weekly 0.7 https://trial.medpath.com/news/b629732e894f192d/cf-foundation-invests-15m-in-recode-therapeutics-to-boost-cf-gene-editing 2024-11-20T00:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/2f61c419908ef54f/astrazeneca-s-andexxa-could-be-headed-for-withdrawal-after-us-fda-s-negative 2024-11-20T00:21:44+00:00 weekly 0.7 https://trial.medpath.com/news/46255192148953e1/ai-powered-innovation-zasocitinib-s-journey-to-precision-inhibition-dermatology-times 2024-11-20T00:15:28+00:00 weekly 0.7 https://trial.medpath.com/news/3868da7c077ca499/und-research-team-approved-for-pediatric-eye-disease-group-clinical-trials 2024-11-20T00:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/baa7ec0f005316e9/vir-biotechnology-promising-data-and-strategic-developments-justify-buy-rating 2024-11-20T00:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/4a3ff6a3f288d8ef/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-20T00:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/a7203b232b54c7c6/pharmaceuticals-volume-17-issue-11-november-2024 2024-11-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fc2a26b7e3b565ef/cero-therapeutics-holdings-inc-sec-10-q-report-tradingview 2024-11-19T23:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/2e37d16c1af39cdc/non-binding-guidance-clinical-trial-diversity-in-focus-lexology 2024-11-19T23:18:50+00:00 weekly 0.7 https://trial.medpath.com/news/f52312ea99596cbb/parexel-introduces-fda-expedited-designation-trends-for-advanced-therapies 2024-11-19T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/f30b6f26d0336757/pfizer-expands-drug-discovery-alliance-with-two-more-flagship-startups-for-cancer-and-obesity-research 2024-11-19T22:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/aa2b3e036dc0dd64/university-hospitals-only-health-system-in-northeast-ohio-offering-fda-approved 2024-11-19T22:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/ef72936f26f1a72f/first-generic-propofol-injectable-emulsion-for-dogs-receives-fda-approval-dvm360 2024-11-19T22:24:52+00:00 weekly 0.7 https://trial.medpath.com/news/f399324c3632b153/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology-shows-significant-reduction-in-systemic-lupus-erythematosus-disease-activity 2024-11-19T22:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/bd49a62d9277e4ee/new-phase-2-synapse-cmt-study-to-test-effects-of-nmd670-in-charcot-marie-tooth 2024-11-19T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/e5ca01a3316f30ed/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase-alfa-met-primary-endpoints 2024-11-19T22:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/b2e1866bfcb076a2/positive-phase-3-results-announced-for-jnj-2113-treatment-of-psoriasis-hcplive 2024-11-19T22:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/edf8bbc413378127/lly-oral-cholesterol-drug-lowers-lipoprotein-levels-in-phase-ii-study-yahoo-finance 2024-11-19T21:54:02+00:00 weekly 0.7 https://trial.medpath.com/news/3f9dc8b1b9fa44f0/all-in-the-blood-new-way-to-detect-drug-resistance-in-ovarian-cancer-patients-biomelbourne-network 2024-11-19T21:53:13+00:00 weekly 0.7 https://trial.medpath.com/news/320cf859bf60f171/abk-biomedical-announces-fda-ide-stage-2-approval-for-route90-a-prospective-multi 2024-11-19T21:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/4fc34c1660270f93/ai-to-spot-aria-fda-says-yes-alzforum 2024-11-19T21:49:43+00:00 weekly 0.7 https://trial.medpath.com/news/8549d772fb4b8243/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:46:37+00:00 weekly 0.7 https://trial.medpath.com/news/905b53a3facce501/pharmather-announces-update-on-fda-new-drug-application-for-ketamine-biospace 2024-11-19T21:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/554941c99464803a/quralis-anqur-clinical-trial-of-qrl-201-in-als-advances-to-dose-range-finding-drf 2024-11-19T21:41:40+00:00 weekly 0.7 https://trial.medpath.com/news/8f64b5799db85103/sangamo-s-novel-gene-therapy-for-chronic-pain-gets-fda-clearance-for-clinical-trials 2024-11-19T21:25:06+00:00 weekly 0.7 https://trial.medpath.com/news/865941438e5fe6fc/fda-says-no-to-astellas-geographic-atrophy-drug-pharmaphorum 2024-11-19T21:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/c1ea0ad811f7b7c8/navigating-decentralized-clinical-trials-with-fda-s-guidance-law360 2024-11-19T21:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/6a9cb9fe9444c78b/regen-biopharma-inc-expands-vision-for-phase-1-clinical-trial-of-hemaxellerate 2024-11-19T21:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/c67eb381a3b23642/lindis-biotech-partners-with-pharmanovia-for-catumaxomab-launch-webdisclosure 2024-11-19T21:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/edd0b939a8e83d7d/alpha-tau-medical-announces-third-quarter-2024-financial-results-and-provides-corporate-update 2024-11-19T21:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/ac89dd76f5ccc6ce/cardiovascular-researchers-dramatically-reduce-size-and-severity-of-stroke-using-antidiabetic-drug-in-preclinical-models 2024-11-19T21:11:18+00:00 weekly 0.7 https://trial.medpath.com/news/d3bf4fd40fba0294/abbott-reports-positive-amplatzer-amulet-data-in-head-to-head-trial-with-boston-scientific-s-watchman 2024-11-19T21:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/103674dae75e4a1e/new-path-for-a-gene-therapy-trial-at-nih-for-a-rare-metabolic-disease 2024-11-19T20:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/351e5181a37e5fd4/chmp-issues-positive-opinion-for-marketing-authorisation-of-aflibercept-biosimilar-fyb203 2024-11-19T20:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/43212e306a27d14d/endoquest-robotics-applies-for-fda-approval-for-its-new-robotic-surgery-device 2024-11-19T20:46:12+00:00 weekly 0.7 https://trial.medpath.com/news/11765d020ac04237/first-patient-dosed-in-trial-for-adicet-s-t-cell-therapy-adi-100-in-autoimmune-disease 2024-11-19T20:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/78539e8e90f2dd64/the-liver-meeting-2024-bausch-health-presents-phase-3-study-design-for-investigational 2024-11-19T20:31:17+00:00 weekly 0.7 https://trial.medpath.com/news/298f0ee212290dfa/uvax-bio-announces-interim-results-from-a-phase-1-clinical-trial-evaluating-its-hiv-1-vaccine 2024-11-19T20:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/9ef1fcd81b845650/merck-s-phase-3-study-of-subcutaneous-keytruda-to-treat-nsclc-meets-primary-goals 2024-11-19T20:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/ac2e7604495066a5/driving-efficiency-and-roi-in-clinical-trials 2024-11-19T20:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/3cdce9113a7915d3/ale-p02-gains-fda-fast-track-status-in-cldn1-solid-tumors-targeted-oncology 2024-11-19T20:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/249eb328e32140fa/phase-3-arise-trial-of-parkinson-therapy-solengepras-begins-dosing-neurology-live 2024-11-19T20:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/d96187d3336e0cba/jnj-2113-shows-promising-phase-3-results-for-plaque-psoriasis-dermatology-times 2024-11-19T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/96c6553db05127b4/head-to-head-trial-to-compare-64cu-sar-bispsma-and-68ga-psma-11-pet-ct 2024-11-19T20:03:50+00:00 weekly 0.7 https://trial.medpath.com/news/7046703cb943961a/non-binding-guidance-clinical-trial-diversity-in-focus-insights-ropes-gray-llp 2024-11-19T20:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/b823e05a7563551b/new-treatment-for-potentially-deadly-graft-versus-host-disease-science-x 2024-11-19T20:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/3d4c1c02726a3285/nih-develops-ai-algorithm-to-streamline-clinical-trial-matching-massdevice 2024-11-19T19:45:25+00:00 weekly 0.7 https://trial.medpath.com/news/f06162f4e6713f6a/fda-issues-crl-to-astellas-supplemental-new-drug-application-for-avacincaptad-pegol 2024-11-19T19:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/e864397c92a3af27/ocugen-announces-positive-preliminary-data-from-ocu410-phase-1-clinical-trial-for 2024-11-19T19:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/7a55c158b08ed262/covid-could-cure-cancer-researchers-make-astonishing-discovery-in-tumour-regression 2024-11-19T19:09:11+00:00 weekly 0.7 https://trial.medpath.com/news/1ffdfcabc78ce259/an-understudied-dementia-soon-to-get-a-pair-of-phase-ii-readouts-biocentury 2024-11-19T18:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/d34727372592ce5c/publication-of-positive-phase-ii-clinical-data-for-fg001-in-patients-with-head-and-neck-cancer 2024-11-19T18:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/f4fd0879327cb01f/fda-approves-car-t-cell-therapy-for-refractory-b-cell-precursor-acute-lymphoblastic-leukemia 2024-11-19T18:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/c2178a914b7a884f/lantern-pharma-announces-first-patient-dosed-in-japan-for-the-expansion-cohort-in-biospace 2024-11-19T18:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/a0bff467a5fe03ab/celebrating-a-personal-milestone-and-an-fda-approval-aadc-news 2024-11-19T18:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/45754d20e4c6db7e/first-in-class-leukemia-treatment-approved-by-fda-webmd 2024-11-19T18:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/257442a04ee7b6dd/aha-2024-zerlasiran-shows-promising-phase-ii-results-for-elevated-lipoprotein-a-yahoo 2024-11-19T18:29:47+00:00 weekly 0.7 https://trial.medpath.com/news/33168158e9dda5f4/quilt-3-032-trial-anktiva-achieves-high-response-rate-in-bcg-unresponsive-nmibc 2024-11-19T18:28:02+00:00 weekly 0.7 https://trial.medpath.com/news/45e67b7eb8266b78/dapirolizumab-pegol-phase-3-data-presented-at-the-american-college-of-rheumatology 2024-11-19T18:18:52+00:00 weekly 0.7 https://trial.medpath.com/news/2bd7355049bda4fe/newamsterdam-pharma-presents-additional-data-from-pivotal-phase-3-brooklyn-clinical 2024-11-19T18:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/c92492c485bd8726/taho-pharmaceuticals-initiates-u-s-phase-iii-clinical-trial-of-tah3311-antithrombotic-oral 2024-11-19T18:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/30a9c6b74a0f6f7c/phio-pharmaceuticals-announces-completion-of-enrollment-in-second-cohort-in-phase-1b 2024-11-19T18:17:19+00:00 weekly 0.7 https://trial.medpath.com/news/6371e9bfd0d95cda/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer-biospace 2024-11-19T18:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/0f8b7633d5d3e88a/covid-might-cure-cancer-no-you-didn-t-read-that-wrong-the-independent 2024-11-19T18:10:57+00:00 weekly 0.7 https://trial.medpath.com/news/019d839199b92dee/eye-on-pharma-eu-aflibercept-approvals-biosimilars-canada-campaign-celltrion-data 2024-11-19T18:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/b55bc3169f4cdd15/incyte-stock-slumps-after-firm-scraps-drug-pauses-enrollment-in-other-study 2024-11-19T17:58:47+00:00 weekly 0.7 https://trial.medpath.com/news/3ae43d999e90c215/mesothelioma-treatment-center-marks-20th-year-of-precision-medicine-treatment 2024-11-19T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/05eee0dce070b0e6/fda-approves-foundationone-liquid-cdx-as-diagnostic-tool-for-nsclc-cancer-network 2024-11-19T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/da360565dd29edfb/performance-of-first-line-chemotherapy-regimens-in-unresectable-advanced-or-metastatic 2024-11-19T17:40:57+00:00 weekly 0.7 https://trial.medpath.com/news/1c1a2ddf9401334a/aha-2024-zerlasiran-shows-promising-phase-ii-results-for-elevated-lipoprotein-a 2024-11-19T17:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/1c72d3cb748569fc/fda-grants-breakthrough-therapy-designation-for-nipocalimab-to-treat-sjogren-disease 2024-11-19T17:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/96b31760b70ba1ac/analyst-says-biotech-s-data-supports-advancement-into-phase-iii-the-streetwise-reports 2024-11-19T17:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/c7d11226a8edabeb/subcutaneous-pembrolizumab-plus-chemo-meets-pharmacokinetic-end-points-in-nsclc 2024-11-19T17:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/fb1d72cfcbf53396/the-chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203 2024-11-19T17:19:48+00:00 weekly 0.7 https://trial.medpath.com/news/8b6fbbd2820e62b2/sen-jam-pharma-launches-phase-ii-trial-of-hangover-prevention-treatment-yahoo 2024-11-19T17:19:34+00:00 weekly 0.7 https://trial.medpath.com/news/3f2cfb72ba0c234a/colchicine-fails-to-reduce-cardiovascular-events-after-myocardial-infarction-but-increases 2024-11-19T17:17:09+00:00 weekly 0.7 https://trial.medpath.com/news/2d0a7597d7cc4105/zacks-sees-600-upside-in-vaping-addiction-drug-maker-achieve-life-sciences-kursiv-kz 2024-11-19T17:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/1c467190e51f657e/risks-in-fda-approved-medical-device-and-flaws-in-fda-procedures-exposed-with-help 2024-11-19T17:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/5aada8bb6f7db7ff/gsk-s-phase-iii-trial-of-linerixibat-shows-promise-for-pbc-itch-by-investing-com 2024-11-19T16:57:13+00:00 weekly 0.7 https://trial.medpath.com/news/ba53e3dfa8beba39/astellas-application-rejected-by-fda-cytokinetics-strikes-licensing-deal-with-bayer 2024-11-19T16:54:39+00:00 weekly 0.7 https://trial.medpath.com/news/1402b236e30aea0e/under-the-skin-keytruda-comparable-to-infused-version-in-phase-3-study-merck-says 2024-11-19T16:53:36+00:00 weekly 0.7 https://trial.medpath.com/news/ee6db97a79740092/fda-grants-fast-track-designation-to-ale-p02-for-cldn1-squamous-solid-tumors 2024-11-19T16:49:47+00:00 weekly 0.7 https://trial.medpath.com/news/1f72ba1c042e4ec5/onward-receives-grant-to-study-bci-in-restoring-movement-after-stroke-massdevice 2024-11-19T16:33:36+00:00 weekly 0.7 https://trial.medpath.com/news/940efb8e61a279e9/genedx-launches-innovative-programs-to-accelerate-rare-disease-diagnosis-and-drug-development 2024-11-19T16:33:24+00:00 weekly 0.7 https://trial.medpath.com/news/5cc309d419a92235/aha-2024-muvalaplin-shows-promising-phase-ii-results-for-elevated-serum-lipoprotein-a 2024-11-19T16:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/2c02f252fe772663/j-j-pill-clears-skin-in-two-late-stage-psoriasis-studies-biopharma-dive 2024-11-19T16:27:59+00:00 weekly 0.7 https://trial.medpath.com/news/22867c8f3b939ae2/novel-anti-igg-drug-hits-mark-in-sjogren-s-patients-medpage-today 2024-11-19T16:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/512025f220f2f4dd/sen-jam-pharma-launches-phase-ii-trial-of-hangover-prevention-treatment 2024-11-19T16:21:45+00:00 weekly 0.7 https://trial.medpath.com/news/468a2ace942bcb27/new-ai-method-measures-cancer-severity-using-pathology-reports-newswise 2024-11-19T16:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/119bb0d9a301b9fb/dr-kim-on-the-cares-310-study-of-rivoceranib-plus-camrelizumab-in-first-line-hcc 2024-11-19T16:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/63997c1d38abfcc2/dr-sharma-on-the-checkmate-901-study-in-advanced-urothelial-cancer-onclive 2024-11-19T16:09:57+00:00 weekly 0.7 https://trial.medpath.com/news/2075f5c232bc0d20/bendamustine-obinutuzumab-combo-may-improve-cr-rates-in-mcl-oncology-nursing-news 2024-11-19T16:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/cb14e6d84ed5d664/vir-biotechnology-announces-results-from-solstice-trial-markets-insider 2024-11-19T16:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/c4d0426f41e44513/biogen-ucb-reveal-details-behind-surprise-late-stage-win-in-lupus-eyes-second-phase-iii 2024-11-19T16:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/c09f120672c6194a/fda-accepts-nda-from-aldeyra-therapeutics-for-reproxalap-for-dry-eye-ophthalmology-times 2024-11-19T16:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/5a28c0455279f651/kyv-101-granted-orphan-drug-status-for-mg-in-europe-myasthenia-gravis-news 2024-11-19T15:58:59+00:00 weekly 0.7 https://trial.medpath.com/news/cb8778431cb91390/lipoprotein-a-lowering-draw-between-lilly-and-silence-inside-precision-medicine 2024-11-19T15:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/47147576ecd7cd0f/immunotherapy-shows-potential-to-treat-deadly-thyroid-cancer-feinberg-news-center 2024-11-19T15:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/5a1c6b3f9f1dd342/ema-recommends-nuz-001-for-orphan-designation-in-europe-als-news-today 2024-11-19T15:44:57+00:00 weekly 0.7 https://trial.medpath.com/news/9709201fdb5dbbca/2025-gold-report-for-copd-meilan-han-md-ms-discusses-addition-of-dupilumab-ensifentrine 2024-11-19T15:36:57+00:00 weekly 0.7 https://trial.medpath.com/news/64eb2f795ae46dbd/the-dodgers-world-series-run-brought-attention-to-a-rare-disease-annexon-is-stepping-up 2024-11-19T15:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/607ada8295785e50/new-ai-tool-connects-patients-to-clinical-trials-faster-azorobotics 2024-11-19T15:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/5b7d458b388bc2e8/leapcure-builds-on-fda-s-guidance-for-diversity-in-clinical-trials-pr-newswire 2024-11-19T15:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/ee7b834d8c3c1844/new-treatment-emerges-for-dangerous-graft-vs-host-disease-mirage-news 2024-11-19T15:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/8ad8bcf12920261b/spyglass-pharma-completes-enrollment-in-phase-i-ii-study-of-its-long-term-drug-delivery 2024-11-19T15:04:41+00:00 weekly 0.7 https://trial.medpath.com/news/39800c79fd138bc9/attr-cm-approval-for-bridgebio-could-trigger-tight-race-with-pfizer-biospace 2024-11-19T15:01:38+00:00 weekly 0.7 https://trial.medpath.com/news/ef20dcfab1897b18/merck-s-subcutaneous-keytruda-meets-expectations-in-phase-iii-biospace 2024-11-19T14:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/23327ca515876c94/taho-pharmaceuticals-initiates-u-s-phase-iii-clinical-trial-of-tah3311-antithrombotic-oral 2024-11-19T14:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/fb9ee4defb1a9395/napo-therapeutics-wins-best-pharma-innovator-award-advances-rare-disease-drug-trials 2024-11-19T14:40:44+00:00 weekly 0.7 https://trial.medpath.com/news/25e391063e83c5c8/fda-grants-fast-track-designation-to-potential-gene-therapy-for-osteoarthritis-of-the-knee 2024-11-19T14:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/6bfd61e30c6ebfe2/j-j-psoriasis-pill-in-a-tier-of-its-own-after-phase-iii-win-citeline 2024-11-19T14:37:35+00:00 weekly 0.7 https://trial.medpath.com/news/3ae23ec093bcc82f/ord-sponsored-clinical-trials-registration-and-submission-of-summary-results 2024-11-19T14:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/34e467e627e8ed47/abk-biomedical-announces-fda-ide-stage-2-approval-for-route90-a-prospective-multi 2024-11-19T14:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/f9ef788faaf84647/soligenix-announces-formation-of-european-medical-advisory-board-for-cutaneous-t-cell 2024-11-19T14:07:36+00:00 weekly 0.7 https://trial.medpath.com/news/6d70637f755c8a07/fda-oks-foundationone-liquid-cdx-for-tepotinib-in-metex14-skipping-nsclc 2024-11-19T14:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/fcb0f3ee59f335dd/nih-algorithm-matches-patients-to-clinical-trials-pharmaphorum 2024-11-19T13:53:53+00:00 weekly 0.7 https://trial.medpath.com/news/40201a5d8700e338/cardiol-to-advance-cardiolrx-to-phase-iii-trial-following-positive-results-the-deep-dive 2024-11-19T13:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/029f04371cffd4ec/samsung-bioepis-has-received-product-approval-for-its-eilean-biosimilar-ofubiztm 2024-11-19T13:36:35+00:00 weekly 0.7 https://trial.medpath.com/news/bda5fcffe466f5d7/us-fda-issues-complete-response-letter-for-avacincaptad-pegol-izervay-astellas-pharma-inc 2024-11-19T13:35:58+00:00 weekly 0.7 https://trial.medpath.com/news/d95db1823f4aac60/envveno-medical-seeks-fda-approval-for-venovalve-by-investing-com 2024-11-19T13:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/05ace2d8f50280ea/envveno-medical-submits-the-venovalve-pma-application-seeking-fda-approval 2024-11-19T13:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/26dad06c6e423938/sen-jam-pharmaceutical-advances-first-in-class-fda-regulated-hangover-prevention 2024-11-19T13:32:15+00:00 weekly 0.7 https://trial.medpath.com/news/b2fe5112e1e03500/envveno-medical-submits-the-venovalve-pma-application-seeking-fda-approval 2024-11-19T13:30:38+00:00 weekly 0.7 https://trial.medpath.com/news/2b3b0421fb695193/bpgbio-recognized-as-2024-biotech-ai-company-of-the-year-by-biotech-breakthrough-awards 2024-11-19T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/f4c4265b4649e07c/celltrion-announces-phase-3-results-of-actemra-and-prolia-biosimilars-at-u-s-conference 2024-11-19T13:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/0fa2ea63f1d801d8/immunitybio-s-bladder-cancer-drug-shows-71-response-rate-in-key-trial-stock-titan 2024-11-19T13:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/2e36d8668e78fc39/nextcure-s-nc605-shows-promise-in-treating-osteogenesis-imperfecta-with-enhanced-bone-quality 2024-11-19T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/10a567224dfd6cc6/biogen-eisai-s-alzheimer-s-drug-lecanemab-receives-chmp-recommendation-pmlive 2024-11-19T13:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/8336f836c646956e/tryptamine-therapeutics-will-advance-to-trp-8803-psilocin-phase-2-clinical-trials 2024-11-19T13:05:49+00:00 weekly 0.7 https://trial.medpath.com/news/76ffe3f802774977/spyglass-pharma-completes-enrollment-in-phase-i-ii-study-of-globenewswire 2024-11-19T13:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/a204c3e1ecbc5d2b/cognito-therapeutics-showcases-early-stage-cost-effectiveness-of-spectris-therapy-for-alzheimers-disease 2024-11-19T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dedaf30446b35b0f/data-sharing-is-patient-caring-retail-pharmacy 2024-11-19T12:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/f5e00f224caf2040/soligenix-announces-formation-of-european-medical-advisory-board-for-cutaneous-t-cell 2024-11-19T12:56:45+00:00 weekly 0.7 https://trial.medpath.com/news/63ef30534c19a15a/pi-insights-from-a-heart-failure-trial-part-2-clinical-leader 2024-11-19T12:50:31+00:00 weekly 0.7 https://trial.medpath.com/news/35ac0d780eb00108/ocucool-revolutionizes-eye-injections-with-fda-approval-but-faces-reimbursement-kbr 2024-11-19T12:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/0aa4a18472a0faa5/biogen-ucb-s-lupus-drug-shows-consistent-efficacy-across-endpoints-over-time 2024-11-19T12:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/9fbb6f40fc337ed7/icpo-foundation-partners-with-munich-precision-oncology-globenewswire 2024-11-19T12:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/a80a8f64d3d35abf/neuron23-advances-precision-medicine-in-parkinson-s-disease-with-digital-biomarker-driven-phase-2-trial 2024-11-19T12:31:00+00:00 weekly 0.7 https://trial.medpath.com/news/39b037514ae24f66/atamyo-therapeutics-gene-therapy-ata-200-cleared-for-us-trial-in-lgmd-type-2c-r5 2024-11-19T12:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/cd4a231c53ee2e25/taho-pharmaceuticals-initiates-u-s-phase-iii-clinical-trial-of-tah3311-antithrombotic-oral 2024-11-19T12:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/164dbb972ff462e6/taho-pharmaceuticals-initiates-u-s-phase-iii-clinical-trial-of-tah3311-antithrombotic-oral 2024-11-19T12:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/be1a6489e8f1c385/j-j-plots-filings-after-psoriasis-drug-clears-phase-3-test-pharmaphorum 2024-11-19T12:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/61bf5f8a1409529c/resolution-therapeutics-secures-spanish-liver-disease-trial-approval-clinical-trials-arena 2024-11-19T12:04:51+00:00 weekly 0.7 https://trial.medpath.com/news/646bb3b08284053a/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus-relentless-itch-in-primary 2024-11-19T11:55:28+00:00 weekly 0.7 https://trial.medpath.com/news/96ffc290f4f314d5/alkeus-gets-fda-regulatory-designations-for-gildeuretinol-alk-001 2024-11-19T11:50:44+00:00 weekly 0.7 https://trial.medpath.com/news/8b003e32e922f174/merck-announces-phase-3-trial-of-subcutaneous-pembrolizumab-with-berahyaluronidase 2024-11-19T11:48:19+00:00 weekly 0.7 https://trial.medpath.com/news/6320792a27892592/blenrep-shows-overall-survival-benefit-in-dreamm-7-phase-iii-trial-for-relapsed-refractory 2024-11-19T11:43:53+00:00 weekly 0.7 https://trial.medpath.com/news/717efcc7ec77b636/intellia-therapeutics-price-target-lowered-by-wells-fargo 2024-11-19T11:30:42+00:00 weekly 0.7 https://trial.medpath.com/news/29de5960072655d0/shingles-vaccination-rates-show-significant-rise-among-asthma-patients-study-reveals-major-disparities 2024-11-19T11:29:27+00:00 weekly 0.7 https://trial.medpath.com/news/3feb77f398508a35/vir-biotechnology-announces-results-from-solstice-trial-tipranks-com 2024-11-19T11:28:31+00:00 weekly 0.7 https://trial.medpath.com/news/5cc0f1858432bb0f/eli-lilly-announces-positive-phase-2-results-for-muvalaplin-against-heart-disease 2024-11-19T11:26:07+00:00 weekly 0.7 https://trial.medpath.com/news/3a55c915586dea1b/fda-approves-first-ever-gene-therapy-to-be-directly-administered-to-the-brain 2024-11-19T11:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/f6e4fb0ca2b986cd/newer-blood-thinner-edoxaban-cuts-odds-for-stroke-after-heart-valve-surgery 2024-11-19T11:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/e9b19af1dc89c088/small-interfering-rna-shows-cumulative-lp-a-reduction-with-successive-doses 2024-11-19T11:09:22+00:00 weekly 0.7 https://trial.medpath.com/news/eefeb056bac568d1/fda-approves-revuforj-to-treat-r-r-acute-leukemia-with-kmt2a-translocation 2024-11-19T11:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/d22606503d5ee6bd/new-postmarketing-registry-to-evaluate-real-world-safety-and-patient-experience-with 2024-11-19T11:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/8d80e4e2c6471380/newer-blood-thinner-cuts-odds-for-stroke-after-heart-valve-surgery 2024-11-19T11:04:40+00:00 weekly 0.7 https://trial.medpath.com/news/125145b72012364a/ablation-best-treatment-for-rapid-heartbeat-in-heart-attack-survivors 2024-11-19T11:02:33+00:00 weekly 0.7 https://trial.medpath.com/news/67e3cbaaf2447dbf/adding-blood-thinners-to-a-fib-treatment-won-t-prevent-strokes-help-cognition 2024-11-19T11:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/ba6f04e2e7da79a8/nih-develops-ai-algorithm-to-streamline-clinical-trial-matching-news-medical 2024-11-19T10:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/b94f30a9b90fe4a9/pll-therapeutics-obtains-authorization-to-start-phase-i-ii-trial-in-australia-for-patients-with 2024-11-19T10:49:48+00:00 weekly 0.7 https://trial.medpath.com/news/35e0b9e59c820b76/chmp-recommends-astrazeneca-s-tagrisso-for-eu-approval-for-nsclc-yahoo-finance 2024-11-19T10:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/2c2b5e15f605b3a0/pharmanovia-signs-novel-biologic-in-licensing-agreement-with-lindis-biotech-to-financial-post 2024-11-19T10:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/a1d8cc3bc192f1f7/biosimilar-referencing-aflibercept-from-samsung-bioepis-approved-by-european-commission 2024-11-19T10:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/244ec2270c8601ba/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and 2024-11-19T09:49:31+00:00 weekly 0.7 https://trial.medpath.com/news/b4954f0ec5729318/european-union-recommends-approval-of-astrazeneca-s-tagrisso-for-patients-pharmabiz-com 2024-11-19T09:32:14+00:00 weekly 0.7 https://trial.medpath.com/news/da32269800a498af/enterobiotix-completes-patient-recruitment-in-phase-2-triumph-study-of-ebx-102-pharmabiz-com 2024-11-19T09:31:34+00:00 weekly 0.7 https://trial.medpath.com/news/ed4a8c232ad722cf/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to 2024-11-19T09:29:17+00:00 weekly 0.7 https://trial.medpath.com/news/0b30b4c5ecb436d3/chmp-recommends-astrazeneca-s-tagrisso-for-eu-approval-for-nsclc 2024-11-19T09:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/311ce927f19b67a6/chmp-recommends-astrazeneca-s-tagrisso-for-eu-approval-for-nsclc-yahoo 2024-11-19T09:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/0065f03640b213f9/resonance-contracted-by-major-global-pharma-company-for-clinical-drug-trial-worth 2024-11-19T08:48:24+00:00 weekly 0.7 https://trial.medpath.com/news/24b4a2475d9a5b4b/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to 2024-11-19T08:42:52+00:00 weekly 0.7 https://trial.medpath.com/news/be4359053a471f1f/curium-completes-enrollment-early-of-phase-3-solar-recur-prostate-cancer-trial 2024-11-19T08:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/dc30034f6c28fb93/resolution-therapeutics-announces-approval-of-clinical-trial-application-by-aemps-to 2024-11-19T08:40:24+00:00 weekly 0.7 https://trial.medpath.com/news/4d139b51171b3a05/cytokinetics-and-bayer-announce-exclusive-licensing-collaboration-for-aficamten-in-japan 2024-11-19T08:31:50+00:00 weekly 0.7 https://trial.medpath.com/news/fbaa70ba03e9d1d7/sec-recommends-approval-of-additional-indication-for-bms-anti-cancer-drug-nivolumab 2024-11-19T08:31:08+00:00 weekly 0.7 https://trial.medpath.com/news/fc9f4ebac66b72e6/allarity-therapeutics-reports-key-progress-in-phase-2-stenoparib-trial-and-strategic 2024-11-19T08:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/eaf664b3ab9d3514/gender-bias-leaves-women-at-risk-in-cardiology-treatment-guidelines-bioworld 2024-11-19T08:09:12+00:00 weekly 0.7 https://trial.medpath.com/news/e436b82825ece275/vir-biotechnology-gets-positive-opinion-on-orphan-drug-designation-for-tobevibar 2024-11-19T08:07:37+00:00 weekly 0.7 https://trial.medpath.com/news/072b9ed70d96785f/vir-s-hepatitis-delta-drug-achieves-100-response-rate-in-phase-2-trial-stock-titan 2024-11-19T08:06:52+00:00 weekly 0.7 https://trial.medpath.com/news/d6a0bb71dcff0cfa/theolytics-doses-first-patient-in-phase-i-iia-trial-of-theo-260-in-ovarian-cancer 2024-11-19T08:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/40b17515e3341e77/nouscom-completes-patient-enrollment-of-randomized-phase-2-globenewswire 2024-11-19T07:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/f7404127a6c59675/insilico-medicine-reports-breakthrough-phase-iia-results-for-ai-driven-ipf-drug-ism001-055 2024-11-19T06:56:43+00:00 weekly 0.7 https://trial.medpath.com/news/12132b5e999ee867/astrazeneca-tagrisso-recommended-for-approval-in-eu-by-chmp-for-patients-with 2024-11-19T06:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/f8ae65d87d96405a/chloroquine-primaquine-therapeutic-response-and-safety-in-patients-with-uncomplicated 2024-11-19T06:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/8d87e9ad72c3a67f/drug-trials-snapshot-miebo-ein-presswire 2024-11-19T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/3acbdb9264a3c28b/breakthrough-drug-step-closer-to-saving-lives-following-mnd-association-campaign 2024-11-19T06:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/42dcb2b1d20beb7b/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/f57f5b776c526710/zenflow-announces-24-million-financing-round-to-fund-fda-filing-commercial-preparation 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/2eea1378d600e733/truebinding-receives-fda-ind-go-ahead-for-parkinson-s-phase-2a-clinical-trial 2024-11-19T06:12:28+00:00 weekly 0.7 https://trial.medpath.com/news/cd4d97d982f3d01c/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-biospace 2024-11-19T06:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/82192f8803b1190f/adicet-opens-enrollment-for-adi-270-phase-1-clinical-trial-in-metastatic-advanced-clear 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/69038e760cb52ee1/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-19T06:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/8227c098a05782b7/lytix-biopharma-q3-2024-positive-clinical-results-and-strategic-advancements-strengthen 2024-11-19T06:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/d8da05a0c5351633/oral-muvalaplin-for-lowering-of-lipoprotein-a-a-randomized-clinical-trial-jama-network 2024-11-19T05:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/2e356e7d69612881/orano-med-breaks-ground-on-265m-thorium-production-site-radiology-business 2024-11-19T05:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/5d6e40fc2d37a9cb/amyloid-related-imaging-abnormalities-in-clinical-trials-of-gantenerumab-in-early 2024-11-19T05:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/6d64c4a3676a60d1/resonance-health-expands-clinical-trial-operations-with-sun-pharmaceutical-agreement 2024-11-19T05:10:45+00:00 weekly 0.7 https://trial.medpath.com/news/9467791aeb68ff34/tonix-pharmaceuticals-reports-positive-phase-3-results-for-tnx-102-sl-in-fibromyalgia 2024-11-19T05:09:27+00:00 weekly 0.7 https://trial.medpath.com/news/29d18d9c32790743/liquid-biopsies-emerge-as-game-changer-for-rapid-gi-cancer-diagnosis-and-treatment-monitoring 2024-11-19T05:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/7465f04ae597466e/ccl2-ccr2-pathway-identified-as-key-driver-of-aggression-in-double-expressor-dlbcl 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bea761dd4a84921e/novel-blood-test-could-revolutionize-lung-cancer-screening-amid-low-ct-scan-adoption 2024-11-19T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c913ff753c84db8d/fda-approves-new-treatment-for-graft-versus-host-disease-labonline 2024-11-19T04:12:55+00:00 weekly 0.7 https://trial.medpath.com/news/8feb2bc1d11330df/patient-treated-with-neurogene-s-investigational-rett-syndrome-gene-therapy-ngn-401-in 2024-11-19T04:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/e92144425108689c/cell-and-gene-therapies-the-global-race-to-cure-everything-pioneering-the-next 2024-11-19T04:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/6cb7729b435423ec/novel-anti-inflammatory-flops-for-hfpef-hfmref-medpage-today 2024-11-19T03:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/effce5648a41db2d/pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sana-biotechnology-inc 2024-11-19T03:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/62a85860628bb8bc/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-and-morningstar 2024-11-19T02:31:37+00:00 weekly 0.7 https://trial.medpath.com/news/1c4f0a033889a675/vir-biotechnology-presents-positive-chronic-hepatitis-delta-clinical-trial-data-yahoo-finance 2024-11-19T02:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/91126863833840ef/linerixibat-shows-positive-phase-iii-results-in-cholestatic-pruritus-in-primary-biliary-cholangitis-pbc 2024-11-19T02:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/5defc46d4c09b600/samsung-bioepis-receives-european-approval-for-ophthalmic-disease-treatment-opuviz 2024-11-19T01:55:16+00:00 weekly 0.7 https://trial.medpath.com/news/20717013a7a83e5c/toripalimab-plus-chemo-approved-in-uk-for-frontline-nasopharyngeal-carcinoma-and-escc 2024-11-19T01:12:52+00:00 weekly 0.7 https://trial.medpath.com/news/10682573582c9f9e/secondary-offering-syndax-wins-revuforj-fda-nod-in-km2a-leukemia-bioworld 2024-11-19T00:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/8a978415248d7273/samsung-bioepis-announced-on-the-19th-that-it-has-finally-obtained-product-approval-for-its-eilean-b 2024-11-19T00:34:25+00:00 weekly 0.7 https://trial.medpath.com/news/2d02f2d7d27b5036/shanghai-vitalgen-advances-vgr-r01-gene-therapy-to-phase-3-trial-for-bietti-crystalline-dystrophy 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/dc0c6312d2c35651/cu-medicine-introduces-asia-s-first-histotripsy-2-0-system-for-liver-tumour-treatment 2024-11-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/b72b9a1e810d2c91/chmp-gives-positive-opinion-for-lecanemab-following-re-examination-of-data 2024-11-18T23:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/d86f8c509e45a2dd/real-world-rrmm-data-explore-dose-deescalation-and-outpatient-use-of-teclistamab 2024-11-18T22:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/018bc95518e8dd3c/fda-authorizes-ai-driven-mri-solution-for-safer-alzheimer-s-treatment 2024-11-18T22:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/f75d342a04634480/open-label-extension-data-confirms-sustained-benefit-of-acoramidis-on-cardiovascular-outcomes-including-statistically-significant-reduction-in-acm-within-36-months 2024-11-18T22:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/7e989239982871b2/muvalaplin-lowered-lipoprotein-a-levels-in-adults-with-high-risk-for-cardiovascular-events-by-up-to-85-at-highest-tested-dose 2024-11-18T22:11:04+00:00 weekly 0.7 https://trial.medpath.com/news/ac1c0961b7d3b5c5/two-lp-a-lowering-therapies-clear-bar-in-kraken-and-alpacar-tctmd-com 2024-11-18T22:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/fb2330a2be255937/fda-approves-first-and-only-drug-for-rare-leukemia-managed-healthcare-executive 2024-11-18T22:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/b0dc53c4073ea2a3/ema-grants-orphan-drug-status-to-vir-biotech-hepatitis-treatments-investing-com 2024-11-18T21:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/651bfa752ce2b462/j-j-s-new-psoriasis-drug-shows-breakthrough-results-in-phase-3-trial-74-success-rate 2024-11-18T21:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/4953794f56cba6e3/incyte-provides-update-on-early-phase-mrgprx2-and-mrgprx4-programs-stock-titan 2024-11-18T21:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/ce13f7dda99a7ff7/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T21:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/5d087aad2cd1c676/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/80b27cae7793dba6/silence-therapeutics-releases-late-breaking-phase-2-zerlasiran-data-daic 2024-11-18T21:29:38+00:00 weekly 0.7 https://trial.medpath.com/news/cf99412213845681/fda-grants-breakthrough-therapy-status-to-nipocalimab-for-sjogren-s-disease 2024-11-18T21:23:03+00:00 weekly 0.7 https://trial.medpath.com/news/0c8c84b2d7f8a02d/kraken-oral-muvalaplin-safely-lowers-lp-a-in-early-stage-trial 2024-11-18T21:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/366a442119002075/data-continue-to-help-shape-cdk4-6-inhibitor-selection-sequencing-in-hr-breast-cancer 2024-11-18T21:19:57+00:00 weekly 0.7 https://trial.medpath.com/news/daa12e3d63b0b983/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/18f8d854d889c7c4/grail-launches-fda-approved-phase-3-trial-for-breakthrough-lung-cancer-blood-test 2024-11-18T21:14:57+00:00 weekly 0.7 https://trial.medpath.com/news/60375d9e1dd50ed0/vir-biotechnology-secures-key-eu-orphan-drug-status-for-hepatitis-delta-treatment 2024-11-18T21:14:47+00:00 weekly 0.7 https://trial.medpath.com/news/7091bd6392a474ad/toragen-inc-provides-update-on-data-from-ongoing-phase-1-clinical-trial-of-tgn-s11-as 2024-11-18T21:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/fb8d800dd74fc041/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T21:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/0ae8763e57a6b8d9/vir-biotechnology-receives-positive-opinion-on-orphan-drug-designation-for-tobevibart 2024-11-18T21:09:33+00:00 weekly 0.7 https://trial.medpath.com/news/8a5b504625b12a8b/two-years-after-its-fda-approval-rebyota-continues-to-show-efficacy-and-safety 2024-11-18T21:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/3e584d7cc1fad295/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-morningstar 2024-11-18T20:45:56+00:00 weekly 0.7 https://trial.medpath.com/news/f25e9b42f9a7966c/vaccine-for-early-parkinson-s-showing-safety-in-phase-2-trial 2024-11-18T20:29:23+00:00 weekly 0.7 https://trial.medpath.com/news/5cfd1d8b4cafaf60/alentis-receives-fda-fast-track-designation-for-ale-p02-for-the-treatment-of-cldn1 2024-11-18T20:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/008bd43ecc3eb9da/antidiabetic-medication-and-asthma-attacks-diabetes-jama-internal-medicine 2024-11-18T20:13:48+00:00 weekly 0.7 https://trial.medpath.com/news/808beadc2f75804c/chmp-recommends-lazertinib-with-amivantamab-to-treat-egfr-mutated-advanced-nsclc 2024-11-18T20:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/49f00d2a045c3e81/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T20:04:32+00:00 weekly 0.7 https://trial.medpath.com/news/8f523d01032dc4f6/in-a-small-international-trial-novel-oral-medication-muvalaplin-lowered-lp-a 2024-11-18T20:00:32+00:00 weekly 0.7 https://trial.medpath.com/news/656671c576f1dcd2/zetagen-therapeutics-announces-first-patients-enrolled-in-phase-2a-clinical-study-of 2024-11-18T19:52:38+00:00 weekly 0.7 https://trial.medpath.com/news/9ef228be16624e33/syndax-s-revuforj-wins-fda-approval-in-aggressive-form-of-leukemia-endpoints-news 2024-11-18T19:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/728e545a84bd56fb/eli-lilly-says-phase-3-trial-of-tirzepatide-met-primary-secondary-endpoints-marketscreener 2024-11-18T19:37:13+00:00 weekly 0.7 https://trial.medpath.com/news/d3f7fe8d8545e661/fda-approval-for-revuforj-issued-to-syndax-pharmaceuticals-inc-quantisnow 2024-11-18T19:34:32+00:00 weekly 0.7 https://trial.medpath.com/news/cc3477064d5edca8/novel-drug-can-reduce-lipoprotein-a-by-more-than-80-cleveland-clinic-newsroom 2024-11-18T19:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/32b7ab3568ad4ae3/comparative-analysis-of-hemodynamic-effects-of-remimazolam-and-propofo-dddt 2024-11-18T19:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/ab6f8525f845d82a/gene-therapy-promising-for-rare-genetic-cardiomyopathy-medpage-today 2024-11-18T19:25:33+00:00 weekly 0.7 https://trial.medpath.com/news/8d04dac818fb01df/scientists-from-barcelona-develop-a-car-t-therapy-for-breast-cancer 2024-11-18T19:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/307c51f6c1c95263/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study-and-open-label-extension-from-muir-and-shasta-2-studies-of-plozasiran 2024-11-18T19:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/5823fc6525ab2697/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-for-the-treatment-of-familial-chylomicronemia-syndrome 2024-11-18T19:11:13+00:00 weekly 0.7 https://trial.medpath.com/news/c431b080e57a4a98/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug-application-for-the-treatment-of-dry-eye-disease 2024-11-18T19:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/803e70a2eeae12f8/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T19:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/566eb18629cf16c6/gene-editing-therapy-shows-promise-in-hereditary-angioedema-medpage-today 2024-11-18T19:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/005e81d0eb2289ca/siren-biotechnology-reveals-srn-101-as-lead-asset-for-high-grade-gliomas-with-both 2024-11-18T19:06:20+00:00 weekly 0.7 https://trial.medpath.com/news/86675b7aaf5abb1a/infigratinib-demonstrates-positive-phase-2-data-in-children-with-achondroplasia 2024-11-18T18:45:16+00:00 weekly 0.7 https://trial.medpath.com/news/a73885560f1bbd57/syndax-pharmaceuticals-leukemia-drug-wins-a-first-in-class-fda-approval 2024-11-18T18:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/8bce34fe23c17a7f/first-brain-injected-gene-therapy-approved-by-fda-webmd 2024-11-18T18:27:36+00:00 weekly 0.7 https://trial.medpath.com/news/7b9fb96251d611a7/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-yahoo-finance 2024-11-18T18:23:51+00:00 weekly 0.7 https://trial.medpath.com/news/8751adb553c161f2/biogen-s-outlook-dims-as-analyst-projects-flat-revenue-until-2026-benzinga 2024-11-18T18:23:17+00:00 weekly 0.7 https://trial.medpath.com/news/b4f3dcd9ed908da2/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations 2024-11-18T18:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/2843f62199aaa113/celltrion-presents-additional-data-from-phase-iii-randomized-controlled-trials-to-further 2024-11-18T18:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/0ac26c612f97a8e0/cellectar-biosciences-reports-financial-results-for-q3-2024-globenewswire 2024-11-18T18:06:31+00:00 weekly 0.7 https://trial.medpath.com/news/aa34614bac0962b1/patient-recruitment-complete-for-high-dose-cohort-of-oral-fasudil-in-phase-2-als-study 2024-11-18T18:06:27+00:00 weekly 0.7 https://trial.medpath.com/news/e4d7ca6cbbe06fd7/ohsu-tests-crispr-gene-editing-technology-to-treat-deadly-heart-condition 2024-11-18T17:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/8bcb9358125bc463/fda-approves-revumenib-for-certain-patients-with-advanced-acute-leukemia-healio 2024-11-18T17:45:43+00:00 weekly 0.7 https://trial.medpath.com/news/e4069557cd0d46f6/cardiol-therapeutics-reports-promising-phase-ii-results-for-recurrent-pericarditis-therapy 2024-11-18T17:37:24+00:00 weekly 0.7 https://trial.medpath.com/news/408da1a824219508/think-surgical-receives-fda-510-k-clearance-for-use-of-linksymphoknee-lsk 2024-11-18T17:36:18+00:00 weekly 0.7 https://trial.medpath.com/news/c80523f00f20722b/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-18T17:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/b2df0909223a5b3b/niaid-exercises-option-to-continue-preclinical-development-of-bolder-biotechnology-s-bbt 2024-11-18T17:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/3adc81a9b52a8270/fda-approves-companion-diagnostic-for-tepotinib-in-mnsclc-harboring-met-exon-14 2024-11-18T17:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/2bbd2c1e464c0688/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T17:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/29c97b98747457e0/the-european-commission-approves-biosimilar-referencing-aflibercept-by-samsung-bioepis 2024-11-18T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/3fbfd68bd00d189e/syndax-secures-fda-ok-for-new-kind-of-leukemia-drug-biopharma-dive 2024-11-18T17:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/06fc732a3ab7831b/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints-yahoo 2024-11-18T17:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/c11b7e37ede311c2/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-the-shoreline-beacon 2024-11-18T17:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/3f963beb2901a459/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T17:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/93ec2a8fcac2a4ab/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis-biospace 2024-11-18T17:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/f447add81c9eaffa/trial-of-cf-gene-therapy-sp-101-begins-dosing-is-still-recruiting 2024-11-18T17:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/cabd436bbeb919e0/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T17:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/bf3a0a7ca16df4af/j-j-positive-chmp-opinion-for-lazcluze-in-lung-cancer-marketscreener 2024-11-18T17:01:57+00:00 weekly 0.7 https://trial.medpath.com/news/2e6823d9af4a47fb/daily-tablet-shows-promise-in-treating-achondroplasia-in-children-news-medical 2024-11-18T16:59:21+00:00 weekly 0.7 https://trial.medpath.com/news/58905ceff8c5a3d5/phase-2-trial-of-rock-inhibitor-bravyl-now-fully-enrolled-als-news-today 2024-11-18T16:58:45+00:00 weekly 0.7 https://trial.medpath.com/news/a003c23badec1442/new-technique-may-allow-for-visualization-of-car-t-cells-postinjection-the-asco-post 2024-11-18T16:57:40+00:00 weekly 0.7 https://trial.medpath.com/news/1e297218443f2865/histosonics-enrolls-first-patients-in-histotripsy-master-study-massdevice 2024-11-18T16:49:55+00:00 weekly 0.7 https://trial.medpath.com/news/b52bb95fc98c9bbe/brightheart-earns-fda-clearance-for-ai-powered-prenatal-heart-ultrasound-tech 2024-11-18T16:49:54+00:00 weekly 0.7 https://trial.medpath.com/news/10479fef413372f4/radiotherapy-with-cetuximab-or-durvalumab-for-advanced-hnscc-2-minute-medicine 2024-11-18T16:47:06+00:00 weekly 0.7 https://trial.medpath.com/news/75fd1686122df2fa/barinthus-bio-shares-ongoing-phase-iib-chronic-hepatitis-b-trial-results-clinical-trials-arena 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/a889e40c8d21694b/tennor-s-phase-iii-antibiotic-trial-meets-all-primary-endpoints 2024-11-18T16:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/0e449d431c67dfb9/european-commission-approves-mirvetuximab-soravtansine-for-fra-platinum-resistant 2024-11-18T16:43:15+00:00 weekly 0.7 https://trial.medpath.com/news/0debe71c2c043528/cardiol-therapeutics-phase-ii-maveric-pilot-clinical-results-in-recurrent-pericarditis 2024-11-18T16:42:40+00:00 weekly 0.7 https://trial.medpath.com/news/fd2815daa283a632/cardiol-s-cardiolrx-shows-major-pain-relief-success-in-phase-ii-pericarditis-trial 2024-11-18T16:42:03+00:00 weekly 0.7 https://trial.medpath.com/news/35b03e378c65fcfc/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/2b912dad0156e30b/fda-endorses-speedy-approval-path-for-regenxbio-duchenne-gene-therapy 2024-11-18T16:37:51+00:00 weekly 0.7 https://trial.medpath.com/news/bc79bc8cdf33cc5c/fda-clears-spectral-4dct-for-precision-in-radiation-oncology 2024-11-18T16:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/669229c0f38ee6d0/abbvie-s-ovarian-cancer-drug-elahere-gets-approval-in-europe-yahoo-finance 2024-11-18T16:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/d29e2ddbf255ee3b/phase-3-trial-of-navenibart-for-hae-planned-for-launch-in-early-2025-angioedema-news 2024-11-18T16:27:51+00:00 weekly 0.7 https://trial.medpath.com/news/7cd51de89bf47cdd/ai-tool-aims-to-accelerate-clinical-trial-patient-recruitment-multiple-sclerosis-news-today 2024-11-18T16:26:36+00:00 weekly 0.7 https://trial.medpath.com/news/97db5b49bfb05109/repurposed-multiple-sclerosis-drug-may-hold-the-cure-for-failing-memory-study-finds 2024-11-18T16:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/380ce26eb045460c/brightheart-receives-fda-clearance-for-ai-powered-fetal-heart-ultrasound-software 2024-11-18T16:22:38+00:00 weekly 0.7 https://trial.medpath.com/news/b8bf2309e0d1ad27/pulmonary-vein-isolation-with-optimized-linear-ablation-for-persistent-af-jama-network 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/65b12622edc3295a/beyond-pulmonary-vein-isolation-bringing-persistent-atrial-fibrillation-in-line-with-alcohol 2024-11-18T16:21:23+00:00 weekly 0.7 https://trial.medpath.com/news/11941c669ae0a440/fda-approves-ptc-therapeutics-gene-therapy-for-aadc-deficiency 2024-11-18T16:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/4dca1f18b8298b89/sacituzumab-tirumotecan-shows-promise-in-pretreated-gynecologic-cancer 2024-11-18T16:07:30+00:00 weekly 0.7 https://trial.medpath.com/news/92205a877cd6076e/177lu-psma-i-t-shows-pfs-benefit-in-mcrpc-targeted-oncology 2024-11-18T16:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/4ee0d542d4a23cca/siren-biotechnology-reveals-srn-101-as-lead-asset-for-globenewswire 2024-11-18T16:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/c8376253eaa2f310/intellia-s-gene-editing-therapy-shows-early-potential-in-rare-heart-condition 2024-11-18T15:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/0425c9cd9f945e91/fda-sets-review-date-for-resubmitted-reproxalap-in-dry-eye-disease 2024-11-18T15:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/edf6db48238c5b90/marking-20-years-of-precision-medicine-in-lung-cancer-treatment 2024-11-18T15:48:25+00:00 weekly 0.7 https://trial.medpath.com/news/020fe225d0cb43f3/crucial-steps-towards-a-cure-my-four-take-homes-from-the-clinical-trials-on-alzheimer-s 2024-11-18T15:48:11+00:00 weekly 0.7 https://trial.medpath.com/news/e4193071c1b22311/enveric-biosciences-trims-losses-eyes-key-drug-approval-for-difficult-to-treat-mental 2024-11-18T15:40:28+00:00 weekly 0.7 https://trial.medpath.com/news/21214db4a990b789/glycogen-storage-disorders-gsd-competitive-landscape-globenewswire 2024-11-18T15:36:03+00:00 weekly 0.7 https://trial.medpath.com/news/cb6a2dd210b4fa96/syndax-pharmaceuticals-shares-retain-buy-rating-after-revuforj-approval-by-investing-com 2024-11-18T15:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/49cf6843db4cba88/discover-upcoming-meetings-fda-action-and-key-insights-in-sclc-and-mcspc 2024-11-18T15:10:44+00:00 weekly 0.7 https://trial.medpath.com/news/3930d5f5f5520e65/adicet-bio-announces-first-lupus-nephritis-patient-dosed-in-phase-1-clinical-trial-of-adi 2024-11-18T15:09:53+00:00 weekly 0.7 https://trial.medpath.com/news/f122ddc16c812f3e/japanese-study-finds-diabetes-drug-that-protects-kidney-health-zee-news 2024-11-18T15:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/e5edcb3da56f8490/amivantamab-lazertinib-combo-approaches-eu-approval-in-egfr-advanced-nsclc 2024-11-18T15:02:52+00:00 weekly 0.7 https://trial.medpath.com/news/4c9f7003934e192b/addition-of-pembrolizumab-to-radiation-therapy-and-surgery-in-stage-iii-soft-tissue 2024-11-18T14:53:28+00:00 weekly 0.7 https://trial.medpath.com/news/2938ab79d5dc7c2c/moldova-approves-precision-biosciences-hbv-gene-editing-trial-the-medicine-maker 2024-11-18T14:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/72e771b4aa8eba3a/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-globenewswire 2024-11-18T14:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/fbf648350b4f0e87/roswell-park-clinical-trial-points-toward-promising-new-therapy-for-most-aggressive-type 2024-11-18T14:28:28+00:00 weekly 0.7 https://trial.medpath.com/news/352706751ea21bd0/boston-scientific-watchman-flx-demonstrates-superiority-to-anticoagulants-in-study 2024-11-18T14:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/46d4075d0406451a/new-treatment-options-provide-effective-management-of-geographic-atrophy 2024-11-18T14:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/ef006542d9827b64/understanding-tumour-growth-variability-in-breast-cancer-xenograft-models-identifies-parp 2024-11-18T14:07:56+00:00 weekly 0.7 https://trial.medpath.com/news/845bc2b56fe366d2/intravenous-infusion-of-exenatide-fails-to-reduce-risks-of-complications-in-heart-surgery-patients 2024-11-18T14:06:19+00:00 weekly 0.7 https://trial.medpath.com/news/ccceedf003098d43/novel-immunotherapy-fk-pc101-explored-in-prostate-cancer-trial-targeted-oncology 2024-11-18T14:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/241d96329a62a70c/why-merck-rolled-the-dice-on-an-unbelievable-early-stage-brain-cancer-drug-pharmavoice 2024-11-18T14:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/02ef6a9c07d7ea11/arrowhead-pharmaceuticals-presents-new-data-at-aha24-from-palisade-phase-3-study 2024-11-18T14:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/ff8e3499773c197e/gilead-s-livdelzi-shows-promise-in-pbc-clinical-trial 2024-11-18T14:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/0e9c8e151cd1958f/nuvectis-pharma-chairman-buys-98400-in-common-stock-investing-com 2024-11-18T14:01:31+00:00 weekly 0.7 https://trial.medpath.com/news/e44e1294ddca97c1/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T14:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/15716195cbbe6882/silo-pharma-s-ptsd-drug-shows-breakthrough-results-in-preclinical-study-stock-titan 2024-11-18T14:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/af9299ff843a230b/novartis-ramps-up-in-radiopharma-and-eli-lilly-adds-zepbound-details-stat-news 2024-11-18T13:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/04dd6696c0e06606/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-quantisnow 2024-11-18T13:47:25+00:00 weekly 0.7 https://trial.medpath.com/news/3c72e6a06f9c2823/cassava-sciences-appoints-freda-nassif-as-chief-commercial-officer-stock-titan 2024-11-18T13:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/ce0c118126470d3d/a-real-world-disproportionality-analysis-of-fda-adverse-event-reporting-system-faers 2024-11-18T13:32:28+00:00 weekly 0.7 https://trial.medpath.com/news/e28d6732b448a371/cerevance-doses-first-patient-in-pivotal-phase-3-arise-globenewswire 2024-11-18T13:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/c84f05ef999b7ce7/novo-nordisk-launches-wegovy-in-china-with-prices-well-below-u-s-fortune 2024-11-18T13:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/cfc1d3893c3278b1/late-breaker-oral-presentation-showing-new-analysis-from-globenewswire 2024-11-18T13:21:35+00:00 weekly 0.7 https://trial.medpath.com/news/b6f40f0be11a344c/elite-pharmaceuticals-receives-fda-approval-for-generic-the-woodstock-sentinel-review 2024-11-18T13:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/f52d276d94343289/actinium-pharmaceuticals-reports-78-6m-cash-position-fda-trial-clearances-in-q3 2024-11-18T13:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/404ce7376bc1afaa/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-quantisnow 2024-11-18T13:16:54+00:00 weekly 0.7 https://trial.medpath.com/news/3777a57a175f539a/arrowhead-pharmaceuticals-submits-new-drug-application-to-u-s-fda-for-plozasiran-biospace 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/6369122f202acdcd/larimar-therapeutics-presents-additional-data-from-phase-1-studies-and-phase-2-dose 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/f12e3a40725e63f7/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T13:16:09+00:00 weekly 0.7 https://trial.medpath.com/news/798a5e3fec71bb8d/vera-therapeutics-appoints-jason-s-carter-as-chief-legal-officer-globenewswire 2024-11-18T13:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/02d5f202f4ac26a5/mbx-biosciences-completes-phase-1-trial-of-diabetes-drug-by-investing-com 2024-11-18T13:12:26+00:00 weekly 0.7 https://trial.medpath.com/news/04594005c1ccfe1b/zolbetuximab-approval-paves-way-for-precision-medicine-in-gastric-and-gej-adenocarcinoma 2024-11-18T13:12:00+00:00 weekly 0.7 https://trial.medpath.com/news/b6ebe41752b8f6fc/sandoz-secures-ec-marketing-nod-for-eylea-biosimilar-afqlir 2024-11-18T13:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/5d15daddd1b7e6e2/surviving-and-thriving-news-cu-anschutz 2024-11-18T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/df1fd8042f61ea89/weekly-report-adhd-epilepsy-in-primary-care-resuscitation-guidance-and-more 2024-11-18T13:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/a40b4df3e4ecb4d1/vaderis-receives-fda-fast-track-designation-for-vad044-for-the-treatment-of-hereditary 2024-11-18T13:05:05+00:00 weekly 0.7 https://trial.medpath.com/news/8c2aad40a482068f/convergent-therapeutics-announces-first-shipments-of-actinium-225-from-cardinal-health 2024-11-18T13:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/2e4d76029b982ff7/allarity-therapeutics-reports-key-progress-in-phase-2-globenewswire 2024-11-18T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/76e2460c6699f033/aldeyra-therapeutics-says-fda-accepts-nda-for-reproxalap-in-dry-eye-disease 2024-11-18T13:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/367d71eb01061060/collaboration-fosters-treatment-advancements-for-young-lymphoma-populations 2024-11-18T13:01:54+00:00 weekly 0.7 https://trial.medpath.com/news/b8b00b67ab0d41ca/abbvie-s-elahere-receives-eu-approval-for-treating-platinum-resistant-ovarian-cancer 2024-11-18T12:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/f86aa82d834f6e0e/arrowhead-seeks-fda-nod-for-rare-disease-drug-by-investing-com 2024-11-18T12:58:25+00:00 weekly 0.7 https://trial.medpath.com/news/e630637451160753/boston-pharma-carves-out-monthly-treatment-niche-in-mash-with-strong-phase-ii-data 2024-11-18T12:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/3b7b6dcfff0bc258/teva-and-immunai-partner-to-improve-clinical-decision-making-pharmatimes 2024-11-18T12:49:41+00:00 weekly 0.7 https://trial.medpath.com/news/94376352de97938a/astrazeneca-s-tagrisso-gets-chmp-nod-for-eu-approval-by-investing-com 2024-11-18T12:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/fae9b18f077f9457/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-wiarton-echo 2024-11-18T12:48:12+00:00 weekly 0.7 https://trial.medpath.com/news/54839ab1dc2fff2d/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure-yahoo 2024-11-18T12:44:03+00:00 weekly 0.7 https://trial.medpath.com/news/2b355fb6ef38d814/arrowhead-s-fcs-drug-shows-80-triglyceride-reduction-in-fda-application-arwr-stock-news 2024-11-18T12:41:43+00:00 weekly 0.7 https://trial.medpath.com/news/61a32653a8a24546/medicus-pharma-ltd-appoints-faisal-mehmud-md-mrcp-as-chief-medical-officer 2024-11-18T12:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/8bd1151bdc57dea7/bms-gets-positive-chmp-opinion-for-opdivo-in-mcrc-treatment 2024-11-18T12:41:41+00:00 weekly 0.7 https://trial.medpath.com/news/84500705313cd18a/cybin-reports-positive-phase-2-data-for-cyb003-demonstrating-breakthrough-12-month 2024-11-18T12:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/7fecc900e4f23c78/cellectar-biosciences-inc-sec-10-q-report-tradingview 2024-11-18T12:36:00+00:00 weekly 0.7 https://trial.medpath.com/news/9bd7d5fbb0636144/chmp-recommends-approval-of-lazcluze-rybrevant-in-eu-for-egfr-mutated-advanced-nsclc 2024-11-18T12:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/340cd7cc2616aeec/fda-approves-syndax-drug-revuforj-for-advanced-leukemia-stat-news 2024-11-18T12:33:20+00:00 weekly 0.7 https://trial.medpath.com/news/b1217b27c0b00e79/merck-gains-rights-to-lanova-s-pd-1-vegf-bispecific-antibody-in-deal-worth-over-3-2bn 2024-11-18T12:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/77926857a61ab2d8/neurogene-provides-update-on-ngn-401-gene-therapy-clinical-trial-for-rett-syndrome 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/74501d19fce41bf4/tennor-announces-positive-topline-results-from-rifasutenizol-phase-iii-trial-for-h-pylori-infection 2024-11-18T12:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/e75095d507b6d900/aldeyra-therapeutics-announces-fda-acceptance-for-review-of-reproxalap-new-drug 2024-11-18T12:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/c268ea1e13a8b5df/bhagirathbhai-r-dholaria-md-on-evaluating-allogeneic-car-t-p-bcma-allo1-in-r-r 2024-11-18T12:14:35+00:00 weekly 0.7 https://trial.medpath.com/news/5c1264a6653aaef6/ai-algorithm-matches-potential-volunteers-to-clinical-trials-release-tech-explorist 2024-11-18T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/news/da26e939f5dd2410/alnylam-reveals-trial-outcomes-of-nucresiran-for-attr-amyloidosis-treatment 2024-11-18T12:13:35+00:00 weekly 0.7 https://trial.medpath.com/news/cd746ff1d44c253b/chmp-recommends-rybrevant-in-combination-with-lazcluze-for-the-first-line-treatment 2024-11-18T12:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/f8b44f1bf9054c44/tonix-pharmaceuticals-presented-data-and-analyses-of-tnx-102-sl-treatment-effects-on 2024-11-18T12:11:31+00:00 weekly 0.7 https://trial.medpath.com/news/b0e9fd6de78a3271/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-18T12:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/4514013f17fca201/larimar-therapeutics-presents-additional-data-from-phase-1-globenewswire 2024-11-18T12:06:13+00:00 weekly 0.7 https://trial.medpath.com/news/05d5d193b2d3409e/rationale-behind-the-recent-fda-pd-1-inhibitor-label-restrictions 2024-11-18T12:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/e3adb450c0b1d7fc/karyopharm-to-present-selinexor-data-at-the-66th-american-society-of-hematology-annual 2024-11-18T12:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/5fddd7f457ad85b9/tonix-s-fibromyalgia-drug-shows-breakthrough-results-in-phase-3-trial-fda-decision-looming 2024-11-18T12:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/254ae4029636415e/adicet-bio-launches-phase-1-trial-for-lupus-drug-with-fda-fast-track-status-acet-stock-news 2024-11-18T12:01:38+00:00 weekly 0.7 https://trial.medpath.com/news/92b70ef1798965df/immatics-announces-third-quarter-2024-financial-results-business-update-and-first-stock-titan 2024-11-18T12:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/caed3dc224281949/brightheart-receives-510-k-clearance-from-fda-for-prenatal-ultrasound-software 2024-11-18T11:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/ab73e8876b943635/abbvie-bags-eu-nod-for-key-drug-from-immunogen-takeover-pharmaphorum 2024-11-18T11:44:23+00:00 weekly 0.7 https://trial.medpath.com/news/fd0ce8809fdbdad8/fda-approves-syndax-s-revuforj-to-treat-leukaemia-yahoo-finance 2024-11-18T11:42:46+00:00 weekly 0.7 https://trial.medpath.com/news/cc91486023981fb8/eyenovia-stock-plummets-following-phase-iii-myopia-trial-failure 2024-11-18T11:40:16+00:00 weekly 0.7 https://trial.medpath.com/news/7e6be79f30eb7094/us-fda-grants-rare-paediatric-disease-designation-to-alveogene-s-novel-inhaled-gene 2024-11-18T11:31:20+00:00 weekly 0.7 https://trial.medpath.com/news/56935eeada703492/bristol-myers-squibb-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-to-treat-adult-with 2024-11-18T11:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/6b05c527be1479f8/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-stock-titan 2024-11-18T11:15:42+00:00 weekly 0.7 https://trial.medpath.com/news/1eb9f557ad986d6d/abbvie-s-elahere-wins-european-approval-for-certain-ovarian-cancers 2024-11-18T11:10:30+00:00 weekly 0.7 https://trial.medpath.com/news/87484c9968196ec2/teprotumumab-ted-treatment-shows-benefits-for-patients 2024-11-18T11:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/cb6be1e6b608b698/elite-pharmaceuticals-receives-fda-approval-for-generic-vyvanse-yahoo-finance 2024-11-18T11:05:28+00:00 weekly 0.7 https://trial.medpath.com/news/209f25f1374ad839/a-new-schizophrenia-treatment-what-the-approval-of-cobenfy-could-mean-for-handling 2024-11-18T11:03:11+00:00 weekly 0.7 https://trial.medpath.com/news/b96775c0bdfeaf4f/greenwich-lifesciences-provides-update-on-corporate-events-globenewswire 2024-11-18T11:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/51ccef6818b30169/hopemed-hopes-for-first-line-inroads-in-endometriosis-associated-pain-citeline 2024-11-18T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/3a2c55e29afdb476/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults 2024-11-18T10:46:51+00:00 weekly 0.7 https://trial.medpath.com/news/edbb2528cc614eb1/fda-approves-syndax-s-revuforj-to-treat-leukaemia-pharmaceutical-technology 2024-11-18T10:45:15+00:00 weekly 0.7 https://trial.medpath.com/news/62e2960b9fca7089/bridgebio-pharma-announces-publication-in-the-new-england-journal-of-medicine-of-phase 2024-11-18T10:41:50+00:00 weekly 0.7 https://trial.medpath.com/news/2410a18d0d667741/tagrisso-recommended-for-eu-approval-laura-company-announcement-markets-data 2024-11-18T10:38:11+00:00 weekly 0.7 https://trial.medpath.com/news/a35d90bbee8fe858/bridgebio-pharma-announces-publication-in-the-new-england-globenewswire 2024-11-18T10:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/035a0b48bbf9ec0c/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-pharmiweb-com 2024-11-18T10:30:11+00:00 weekly 0.7 https://trial.medpath.com/news/22bcc8ebc471d83a/nih-ai-links-volunteers-to-clinical-trials-mirage-news 2024-11-18T10:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/36cf4f850160a386/aha-2024-lerodalciep-provides-promising-results-in-open-label-extension-trial-liberate-ole 2024-11-18T10:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/891f06b0dbc13662/oral-drug-safe-effective-in-kids-with-achondroplasia-medpage-today 2024-11-18T10:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/80c607bdb703be1a/i-was-hoping-for-12-18-months-here-i-am-14-years-later-sue-s-ovarian-cancer-story 2024-11-18T10:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/655487eba244c3cf/a-stronger-ozempic-is-coming-what-to-know-about-cagrisema-novo-nordisk-s-new-weight-loss-drug 2024-11-18T10:01:06+00:00 weekly 0.7 https://trial.medpath.com/news/0f4241b6f8cc6be3/mdt-perspective-innovative-applications-of-stereotactic-body-radiation-therapy-in-metastatic 2024-11-18T09:27:50+00:00 weekly 0.7 https://trial.medpath.com/news/3a4e0956b5e894d4/enterobiotix-completes-phase-2-study-recruitment-of-ebx-102-02-in-irritable-bowel-syndrome 2024-11-18T09:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/89860e45e2970756/trogenix-unveils-revolutionary-platform-to-transform-cancer-treatment-through-precision 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/5e8caed20787dafe/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-with-charcot-marie-tooth 2024-11-18T09:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/399046ef25bd5ddc/syndax-gets-fda-okay-for-first-in-class-leukaemia-drug-pharmaphorum 2024-11-18T09:14:30+00:00 weekly 0.7 https://trial.medpath.com/news/81ef185d7ac8ade3/endo-partners-with-paladin-pharma-to-launch-wynzora-cream-in-canada-chemanalyst 2024-11-18T09:13:42+00:00 weekly 0.7 https://trial.medpath.com/news/b5cc0f31157a23fe/astrazeneca-new-positive-chmp-opinion-for-tagrisso-marketscreener 2024-11-18T08:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/ece8d75a7d770049/can-the-integration-of-new-rules-into-a-clinical-decision-support-system-reduce-the-incidence 2024-11-18T08:37:25+00:00 weekly 0.7 https://trial.medpath.com/news/0b7ef6f3892dbf70/brightheart-secures-fda-clearance-for-first-ai-software-revolutionizing-prenatal-fetal 2024-11-18T08:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/6a99f883819a18bd/ema-s-chmp-recommends-approval-of-bms-opdivo-pharmaceutical-technology 2024-11-18T08:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/3a3f0f577352d630/cure51-launches-nhs-approved-study-with-cambridge-university-hospitals-and-seven 2024-11-18T08:07:23+00:00 weekly 0.7 https://trial.medpath.com/news/6350fd4a8e6af750/eli-lilly-reports-outcomes-from-phase-iii-trial-of-tirzepatide-for-hfpef 2024-11-18T08:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/75c14f4e2dca8ede/fda-accepts-dupixent-resubmission-for-review-in-chronic-spontaneous-urticaria-treatment 2024-11-18T07:31:40+00:00 weekly 0.7 https://trial.medpath.com/news/1dd3551adbafe87d/ema-committee-recommends-approval-of-merck-s-keytruda-plus-chemotherapy-as-first-line 2024-11-18T07:29:54+00:00 weekly 0.7 https://trial.medpath.com/news/90be79bec06f2dba/uk-regulator-mhra-grants-nanomerics-clinical-trials-authorisation-notice-for-its-yahoo-finance 2024-11-18T07:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/ac0562c6446ff6f3/biocryst-launches-orladeyo-r-berotralstat-in-ireland-quantisnow 2024-11-18T07:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/f717c6eea1d4ad46/lift-biosciences-expands-into-ireland-for-manufacturing-clinical-operations 2024-11-18T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/8a16f4e08ca99dad/trogenix-unveils-revolutionary-platform-to-transform-cancer-globenewswire 2024-11-18T07:04:18+00:00 weekly 0.7 https://trial.medpath.com/news/65794b9fc17d3e9c/tagrisso-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-unresectable 2024-11-18T07:03:09+00:00 weekly 0.7 https://trial.medpath.com/news/07e5237067c5b6af/positive-data-from-phase-2-scope-trial-with-scib1-company-announcement-investegate 2024-11-18T07:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/46bf44368c0157a5/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-ipsen 2024-11-18T06:56:34+00:00 weekly 0.7 https://trial.medpath.com/news/d246bf5b6974a5ad/abbvie-s-elahere-wins-eu-approval-35-better-survival-in-ovarian-cancer-treatment 2024-11-18T06:32:31+00:00 weekly 0.7 https://trial.medpath.com/news/16012a8aa2769502/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid 2024-11-18T06:29:57+00:00 weekly 0.7 https://trial.medpath.com/news/39d7f3653065e8eb/fda-grants-breakthrough-therapy-designation-to-johnson-johnson-s-nipocalimab-mychesco 2024-11-18T06:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/87dce773aa3f53ac/european-commission-approves-abbvie-s-elahere-for-platinum-resistant-ovarian 2024-11-18T06:26:57+00:00 weekly 0.7 https://trial.medpath.com/news/5cc051b24703a7ed/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran-biospace 2024-11-18T06:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/7485aff9c45c5d98/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/63f53afbd780fee9/cancer-targeted-technology-receives-fast-track-2-4m-grant-to-develop-an-innovative 2024-11-18T06:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/def1087a1ac5f44f/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab-quantisnow 2024-11-18T06:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/11bcf43627564561/roche-receives-ce-mark-for-ventana-folr1-folr1-2-1-rxdx-assay-as-the-first-ihc 2024-11-18T06:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/eadf6d12e4215b28/nmd-pharma-initiates-phase-2-study-of-nmd670-in-patients-globenewswire 2024-11-18T06:16:33+00:00 weekly 0.7 https://trial.medpath.com/news/5a0210b61d5a3d2a/press-release-sequana-medical-announces-strong-24-month-globenewswire 2024-11-18T06:16:32+00:00 weekly 0.7 https://trial.medpath.com/news/9f450a84b729a992/bylvay-r-odevixibat-data-shows-sustained-improvement-in-severe-itch-and-serum-bile-acid-levels 2024-11-18T06:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/f45dfff3dee34715/bylvay-r-odevixibat-data-shows-sustained-improvement-in-globenewswire 2024-11-18T06:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/d705d753846fd615/roche-secures-ce-mark-for-breakthrough-ovarian-cancer-diagnostic-test-rhhby-stock-news 2024-11-18T06:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/e7edbe8f87813dde/abbvie-receives-european-commission-approval-of-elahere-r-mirvetuximab 2024-11-18T06:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/74d14267940422cd/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-biospace 2024-11-18T06:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/a7c7427db704341c/ipsen-pharma-globenewswire-via-ritzau 2024-11-18T06:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/92bd10dca365b4b6/samsung-bioepis-gets-positive-ema-opinion-for-biosimilars-targeting-amgen-s-prolia-xgeva 2024-11-18T06:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/2805057e19dd15a4/child-thriving-after-becoming-world-s-youngest-to-receive-gene-therapy-for-aadc-deficiency 2024-11-18T05:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/3b062d3de2131205/gilead-s-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-18T05:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/15f7b2bae3e90595/formycon-receives-positive-chmp-opinion-for-fyb203-aflibercept-a-biosimilar-candidate 2024-11-18T05:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/fc2bf6677522f28b/us-fda-accepts-for-review-the-resubmission-of-sbla-for-dupixent-to-treat-chronic 2024-11-18T05:28:59+00:00 weekly 0.7 https://trial.medpath.com/news/3d9567c2a762980b/theralase-r-closes-non-brokered-private-placement-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/23d08d4b81c99057/bio-path-holdings-reports-third-quarter-2024-financial-results-biospace 2024-11-18T05:27:15+00:00 weekly 0.7 https://trial.medpath.com/news/4ea24b438e1fd2f0/abbvie-s-setback-gives-bms-commanding-lead-in-schizophrenia-space-biospace 2024-11-18T05:14:18+00:00 weekly 0.7 https://trial.medpath.com/news/50f43d785b6aecc1/two-antibody-therapy-drugs-to-fight-covid-19-get-approval-from-eu-health-body 2024-11-18T04:57:24+00:00 weekly 0.7 https://trial.medpath.com/news/06e203b6b93edb36/sichuan-kelun-biotech-gains-approval-for-skb571-trials-markets-insider 2024-11-18T04:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/035c032c16aebd11/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-markets-insider 2024-11-18T04:48:37+00:00 weekly 0.7 https://trial.medpath.com/news/6107172de21ee4c6/reconditioned-pacemakers-worked-as-well-as-new-ones-american-heart-association 2024-11-18T04:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/cb3ba7316fb244d9/neuralink-blindsight-implant-receives-fda-breakthrough-designation-usa-herald 2024-11-18T04:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/f955e7a011b44b78/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-markets-insider 2024-11-18T03:49:44+00:00 weekly 0.7 https://trial.medpath.com/news/9ec8a6ce208b7be6/isla-101-phase-2a-b-protect-clinical-trial-progress-update-inn 2024-11-18T03:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/1576bef19d2359d5/ema-committee-recommends-approval-of-bristol-myers-repotrectinib-to-treat-advanced-pharmabiz 2024-11-18T03:28:25+00:00 weekly 0.7 https://trial.medpath.com/news/b9b6c7ff514368fd/dental-artificial-intelligence-ai-diagnostic-solution-development-company-ddh-ceo-heo 2024-11-18T02:47:32+00:00 weekly 0.7 https://trial.medpath.com/news/89807d783f2ca2c2/safety-of-simultaneous-vs-sequential-mrna-covid-19-and-inactivated-influenza-vaccines 2024-11-18T02:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/31ab311d4a4f364e/ema-astrazeneca-vaccine-not-recommended-for-people-with-capillary-bleeding-syndrome 2024-11-18T02:24:46+00:00 weekly 0.7 https://trial.medpath.com/news/c669f0be78b6605b/prostate-cancer-cases-set-to-rise-5-78-by-2028-highlighting-critical-need-for-early-detection 2024-11-18T02:22:07+00:00 weekly 0.7 https://trial.medpath.com/news/1b3976a0fec632a9/european-regulator-endorses-approving-leclaza-combo-therapy-to-treat-nsclc-kbr 2024-11-18T02:12:02+00:00 weekly 0.7 https://trial.medpath.com/news/b035a870240a05c6/news-in-brief-inhalerx-neurotech-international-cannabiz 2024-11-18T01:36:17+00:00 weekly 0.7 https://trial.medpath.com/news/d5eee92573f247f1/impact-of-medication-nonadherence-and-drug-drug-interaction-testing-on-the-management-of 2024-11-18T01:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/eeb75ecb5399eec2/the-global-leader-in-rabies-vaccines-the-serum-free-iterative-rabies-vaccine-of-aim-vaccine 2024-11-18T01:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/2c4d853ab3f17553/rona-therapeutics-presented-positive-phase-1-results-of-rn0191-a-novel-sirna-therapy 2024-11-18T01:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/72b00de438d463ab/sichuan-kelun-biotech-gains-approval-for-skb571-trials-tipranks-com 2024-11-18T00:24:02+00:00 weekly 0.7 https://trial.medpath.com/news/a3ed76794ee55c49/sichuan-kelun-biotech-s-skb535-gains-crucial-drug-approval-tipranks-com 2024-11-18T00:24:01+00:00 weekly 0.7 https://trial.medpath.com/news/4f30692475f0db93/clarity-pharmaceuticals-launches-promising-prostate-cancer-trial-tipranks-com 2024-11-18T00:19:12+00:00 weekly 0.7 https://trial.medpath.com/news/2835be4bdd001472/a-new-israeli-clinical-trial-is-testing-a-tuberculosis-vaccine-to-prevent-alzheimer-s-opinion 2024-11-18T00:14:05+00:00 weekly 0.7 https://trial.medpath.com/news/61150473b129a081/alkeus-pharmaceuticals-receives-fda-rare-pediatric-disease-and-fast-track-designations-for-gildeuretinol-as-a-treatment-for-stargardt-disease 2024-11-18T00:11:54+00:00 weekly 0.7 https://trial.medpath.com/news/aebed3fb13ead82a/icotrokinra-delivered-an-industry-leading-combination-of-significant-skin-clearance-with-demonstrated-tolerability-in-a-once-daily-pill-in-phase-3-topline-results 2024-11-18T00:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/f78f180058e68794/restem-presents-phase-1-data-of-its-ulsc-program-in-globenewswire 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/0bdf6b11394b71a1/quell-therapeutics-and-astrazeneca-advance-car-treg-cell-therapy-for-type-1-diabetes-with-10-million-milestone 2024-11-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2faf249e6d674fa8/diabetes-and-weight-loss-drugs-shown-to-reduce-alcohol-related-hospitalizations-study-finds 2024-11-17T23:05:43+00:00 weekly 0.7 https://trial.medpath.com/news/db3114881ef12573/novel-crispr-cas9-based-promising-in-attr-cardiomyopathy-medpage-today 2024-11-17T23:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/3d43602d11da9087/is-ozempic-the-new-miracle-drug-for-patients-with-osteoporosis-related-knee-pain-ausdoc 2024-11-17T23:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/d3ef1672bc85bce2/reduced-bleeding-with-abelacimab-could-transform-atrial-fibrillation-treatment 2024-11-17T23:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/237d7afd58081686/two-treatments-that-don-t-work-for-osteoarthritis-medpage-today 2024-11-17T22:34:02+00:00 weekly 0.7 https://trial.medpath.com/news/d15b365c24af6d10/memphasys-nears-completion-of-key-trial-for-felixtm-system-tipranks-com 2024-11-17T22:04:12+00:00 weekly 0.7 https://trial.medpath.com/news/3cc89f84959b1d1b/email-nudges-spur-patients-with-a-history-of-acute-mi-to-get-flu-shots-tctmd-com 2024-11-17T22:02:17+00:00 weekly 0.7 https://trial.medpath.com/news/7b37616b3f57a8e7/email-reminders-improved-flu-shot-rates-in-denmark-notably-among-heart-attack-survivors 2024-11-17T21:48:53+00:00 weekly 0.7 https://trial.medpath.com/news/08d978d77f23db40/fda-checking-boxes-on-prea-requirement-exposure-for-otc-acetaminophen-ibuprofen-ndas 2024-11-17T21:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/81ae67588f4535b2/emapalumab-may-improve-response-rates-in-mas-treatment-hcplive 2024-11-17T21:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/6901b9833b99d532/in-pci-for-mi-spironolactone-does-not-meet-primary-endpoints-but-may-show-benefit-in-hf 2024-11-17T21:22:14+00:00 weekly 0.7 https://trial.medpath.com/news/3686cb4e966d40c6/glorious-neither-exenatide-nor-restrictive-oxygenation-boost-cv-surgery-outcomes 2024-11-17T21:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/3d60c7e75156dc1a/barry-a-borlaug-md-impact-of-tirzepatide-on-cardiorenal-end-organ-damage-in-hfpef 2024-11-17T21:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/8efd2ad9b13b354e/spironolactone-a-blood-pressure-medication-may-help-reduce-risk-of-new-heart-failure 2024-11-17T21:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/2f56b126f3574594/genai-breakthrough-new-drug-shows-promising-results-vs-lung-disease-daily-tribune 2024-11-17T20:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/88e440b4ea190e90/fda-moves-to-eliminate-oral-phenylephrine-from-otc-nasal-decongestants 2024-11-17T20:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/f9c2a2525aea5117/sarilumab-allows-steroid-taper-more-frequently-vs-methotrexate-in-polymyalgia-rheumatica-healio 2024-11-17T20:23:52+00:00 weekly 0.7 https://trial.medpath.com/news/c558196efe966132/aha-2024-inclisiran-shows-efficacy-improved-adherence-for-reducing-ldl-c-pharmacy-times 2024-11-17T19:46:00+00:00 weekly 0.7 https://trial.medpath.com/news/7d83dcbe0ec279b2/medical-researchers-to-test-tarantula-venom-for-potential-epilepsy-treatment-abc-news 2024-11-17T19:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/26eb8db4a640f7d7/clinical-trials-are-needed-to-develop-new-medicines-for-children-and-teens-living-with-seizures 2024-11-17T18:34:52+00:00 weekly 0.7 https://trial.medpath.com/news/ee45b3e2f03ce1dc/early-fda-approval-of-revuforj-boosts-syndax-pharmaceuticals-prospects-and-supports 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/9ef7c616468924db/promising-clinical-trial-results-and-future-potential-justify-buy-rating-for-akero-therapeutics 2024-11-17T18:32:03+00:00 weekly 0.7 https://trial.medpath.com/news/508d09f4f77f8708/vir-biotechnology-promising-hepatitis-b-treatment-data-amid-cautious-optimism-and 2024-11-17T18:32:02+00:00 weekly 0.7 https://trial.medpath.com/news/8fe192b88476ac5d/glorious-exenatide-lacks-preventive-effect-on-organ-injury-in-cardiac-surgery-hcplive 2024-11-17T17:32:40+00:00 weekly 0.7 https://trial.medpath.com/news/cdd6073dbeb87a2c/alnylam-presents-new-phase-1-results-for-next-gen-rnai-therapy-nucresiran-in-attr 2024-11-17T15:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/a4f3d6c98d2bd42d/8-health-issues-drugs-like-wegovy-may-treat-besides-weight-loss-study-finds 2024-11-17T15:42:35+00:00 weekly 0.7 https://trial.medpath.com/news/ca2ec47afbde2510/intensive-blood-pressure-control-benefits-people-with-type-2-diabetes-too 2024-11-17T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/7658eee23f888de4/white-button-mushroom-extract-shrinks-tumors-and-delays-their-growth-new-atlas 2024-11-17T15:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/24334191a6b17a94/btk-inhibitor-treatment-options-across-the-lymphoma-landscape-cancer-network 2024-11-17T15:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/f077e4549f7d2477/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-markets-insider 2024-11-17T15:01:02+00:00 weekly 0.7 https://trial.medpath.com/news/4f06ce212f20c0a7/aim-vaccine-s-serum-free-rabies-vaccine-nears-global-market-entry-markets-insider 2024-11-17T15:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/d741e2de7f845a12/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor 2024-11-17T14:54:17+00:00 weekly 0.7 https://trial.medpath.com/news/b6e62ee1c22fedbf/2d4-a-humanized-monoclonal-antibody-targeting-cd132-is-a-promising-treatment-for-nature 2024-11-17T14:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/2ef91b7496119f5f/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:46:43+00:00 weekly 0.7 https://trial.medpath.com/news/71675db2caf43511/alnylam-s-nucresiran-achieves-96-ttr-reduction-in-phase-1-attr-amyloidosis-trial 2024-11-17T14:46:06+00:00 weekly 0.7 https://trial.medpath.com/news/674af104f76c289e/tirzepatide-revolutionizes-heart-failure-treatment-the-pinnacle-gazette 2024-11-17T14:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/5ef4eece57d083da/arbutus-biopharma-s-clinical-trial-shows-promise-for-hepatitis-b-treatment-mychesco 2024-11-17T14:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/d3341aedd5a1d293/alnylam-announces-interim-phase-1-data-of-nucresiran-aln-ttrsc04-showing-rapid 2024-11-17T14:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/190936325d024e80/exenatide-a-glp-1-analog-by-iv-during-cardiac-surgery-did-not-reduce-organ-injury-or-death 2024-11-17T14:23:32+00:00 weekly 0.7 https://trial.medpath.com/news/6b3362f64ca8bcf2/endometriosis-drug-offers-hope-for-sufferers-who-want-children-daily-mail 2024-11-17T14:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/865b1af6a3a9b9bb/is-it-too-late-to-buy-viking-therapeutics-stock 2024-11-17T13:57:04+00:00 weekly 0.7 https://trial.medpath.com/news/3e6f5cfc7e8c537a/ocular-nerve-regrowth-following-use-of-diabetes-drug-modern-retina 2024-11-17T13:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/deb1a5c2ae9ce4e7/nudge-flu-trial-cardiovascular-focused-messaging-boosts-flu-vaccination-rates-among-heart-attack-survivors 2024-11-17T13:45:44+00:00 weekly 0.7 https://trial.medpath.com/news/d12cc9dcea24be43/the-convergence-of-funding-research-and-collaboration-in-paediatric-brain-cancer-clinical-trials 2024-11-17T13:41:43+00:00 weekly 0.7 https://trial.medpath.com/news/1c6b6f98fde7017f/ascentage-pharma-announces-a-new-drug-application-for-its-novel-bcl-2-inhibitor-pr-newswire 2024-11-17T13:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/fef5531b9a25fa55/a-phase-ii-trial-of-ipilimumab-nivolumab-or-ipilimumab-and-nivolumab-with-or-without-nature 2024-11-17T13:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/b940e094038686ba/historic-redlining-and-contemporary-racism-linked-to-reduced-life-expectancy-aha-study-reveals 2024-11-17T13:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/a26df2b712df86fa/is-it-too-late-to-buy-viking-therapeutics-stock-the-globe-and-mail 2024-11-17T12:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/8aff1f8829581601/deep-learning-for-oncologic-treatment-outcomes-and-endpoints-evaluation-from-ct-scans-in 2024-11-17T11:06:17+00:00 weekly 0.7 https://trial.medpath.com/news/5aa27c6e3874da3f/ascentage-pharma-s-lisaftoclax-advances-in-drug-approval-tipranks-com 2024-11-17T10:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/25561aadf0e8fde1/sarclisa-recommended-for-eu-approval-by-chmp-to-treat-transplant-ineligible-newly 2024-11-17T10:31:15+00:00 weekly 0.7 https://trial.medpath.com/news/9c04a2a799ced3e5/eu-regulator-urges-caution-over-russia-s-sputnik-v-vaccine-against-covid-19-telegrafi 2024-11-17T09:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/afb9a43c3fe4ff3c/phase-1-clinical-trial-of-hantaan-and-puumala-virus-dna-vaccines-delivered-by-needle-free-injection 2024-11-17T09:55:13+00:00 weekly 0.7 https://trial.medpath.com/news/07e2ac74d79b7a69/mounjaro-appears-to-be-extremely-effective-at-preventing-diabetes-futurism 2024-11-17T09:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/34277ed778855f73/tirzepatide-officially-puts-glp-1-meds-on-the-map-for-obesity-related-heart-failure 2024-11-17T09:44:24+00:00 weekly 0.7 https://trial.medpath.com/news/5c10bbd2a6778e30/elafibranor-improves-predicted-transplant-free-survival-based-on-globe-uk-pbc-scores 2024-11-17T09:32:38+00:00 weekly 0.7 https://trial.medpath.com/news/8666f07da2bbe58f/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-17T09:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/f06e3dc9582b4571/biontech-to-acquire-clinical-stage-biotechnology-company-biotheus-medical-dialogues 2024-11-17T08:40:18+00:00 weekly 0.7 https://trial.medpath.com/news/1acc43074d167baa/boston-scientific-watchman-flxtm-left-atrial-appendage-closure-device-demonstrates 2024-11-17T08:21:51+00:00 weekly 0.7 https://trial.medpath.com/news/c4a634e6f8d1f64b/rivaroxaban-doesn-t-cut-cognitive-decline-stroke-or-tia-in-younger-af-patients 2024-11-17T08:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/3b4c116ce6aae1ab/intellia-therapeutics-reports-promising-phase-1-trial-results-for-nexiguran-ziclumeran-in 2024-11-17T07:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/b5c11f57e7737039/acurx-pharmaceuticals-presentation-by-dr-kevin-garey-at-the-peggy-lillis-foundation 2024-11-17T06:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/8afa59384304ffdb/5-new-weight-loss-drugs-to-watch-in-the-fight-for-the-next-ozempic-aol-com 2024-11-17T05:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/dd7f0355eed3c055/academic-and-community-partnerships-forge-new-path-in-comprehensive-cancer-care 2024-11-17T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/f97479d1931df674/earnings-call-jaguar-health-reports-revenue-growth-in-q3-2024-investing-com-nigeria 2024-11-17T04:59:12+00:00 weekly 0.7 https://trial.medpath.com/news/9ed9862e6edd1a01/samsung-bioepis-announced-on-the-17th-that-it-received-positive-opinions-on-the-product 2024-11-17T04:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/699a7c2130a3d7e6/tce-therapy-demonstrates-quick-responses-for-systemic-lupus-erthematosus-in-early-data 2024-11-17T03:57:33+00:00 weekly 0.7 https://trial.medpath.com/news/3a89ceb265f161a8/summit-trial-proves-tirzepatide-s-benefit-in-hfpef-with-obesity-hcplive 2024-11-17T03:52:36+00:00 weekly 0.7 https://trial.medpath.com/news/1aad87d31c384d88/aha-2024-providing-feedback-for-pharmacists-improved-care-for-veterans-with-heart-failure 2024-11-17T03:21:43+00:00 weekly 0.7 https://trial.medpath.com/news/e345cb88e7659cc1/intellia-says-crispr-therapy-shows-superior-gain-for-cardiomyopathy-patients-stat-news 2024-11-17T03:17:31+00:00 weekly 0.7 https://trial.medpath.com/news/beffe5592a28b175/tirzepatide-lowered-risk-of-worsening-heart-failure-and-cvd-death-for-obese-adults 2024-11-17T03:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/d6fb2df254867dc6/molecular-testing-reshapes-treatment-landscape-in-advanced-pancreatic-cancer-highlighting-promise-of-ras-inhibitors 2024-11-17T03:00:19+00:00 weekly 0.7 https://trial.medpath.com/news/bf31cfe90f022e27/new-car-t-cell-therapy-breakthrough-brings-new-hope-for-treating-deadly-brain 2024-11-17T02:48:30+00:00 weekly 0.7 https://trial.medpath.com/news/8e7f8075858f4a03/there-is-a-clear-link-between-rare-cases-of-blood-clots-and-astrazeneca-vaccine-says 2024-11-17T02:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/a89cbdc86b827e58/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-quantisnow 2024-11-17T02:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/23ccd1d06e95932a/subcutaneous-infliximab-ct-p13-superior-to-placebo-as-maintenance-therapy-for-ibd 2024-11-17T00:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/559e8a1bddcec2f2/cumberland-pharma-reports-key-clinical-and-business-developments-in-november-2024 2024-11-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/6aebf0881e923ffb/merck-receives-positive-eu-chmp-opinion-for-pembrolizumab-plus-chemotherapy-as-first 2024-11-16T23:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/539e1c03a9a2326f/aha-2024-tirzepatide-lowers-risk-of-worsening-heart-failure-cvd-death-in-adults-with-obesity 2024-11-16T23:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/0ace6f31b61ed951/fda-receives-application-for-dato-dxd-treatment-in-egfr-mutated-nsclc-cure-today 2024-11-16T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/09adb233c6bd41b2/foundation-for-sarcoidosis-research-fsr-receives-globenewswire 2024-11-16T22:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/82b164b356a70608/foundation-for-sarcoidosis-research-fsr-receives-confirmation-from-the-department-of 2024-11-16T22:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/5dfd260cbebc8d3c/jak-inhibitor-succeeds-in-giant-cell-arteritis-trial-medpage-today 2024-11-16T22:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/8ee628eb3bdbf420/vq-101-show-promise-in-interim-phase-1-data-for-gba-parkinson-disease-treatment 2024-11-16T22:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/dfa9b31cb7d46134/biomarin-presents-real-world-evidence-further-supporting-safety-and-efficacy-of-quantisnow 2024-11-16T22:06:53+00:00 weekly 0.7 https://trial.medpath.com/news/fb96b4e6793256f2/belantamab-mafodotin-triplet-boosts-os-over-daratumumab-regimen-in-myeloma 2024-11-16T22:05:34+00:00 weekly 0.7 https://trial.medpath.com/news/db995e10b5968311/fda-rems-program-shows-promising-results-for-mavacamten-in-hypertrophic-pharmacy-times 2024-11-16T21:44:28+00:00 weekly 0.7 https://trial.medpath.com/news/54aab9893b9823b6/fenofibrate-as-an-adjunct-therapy-for-ulcerative-colitis-targeting-in-dddt 2024-11-16T21:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/9e5fd678ff68b951/intellia-announces-first-clinical-evidence-from-ongoing-phase-1-study-that-nexiguran 2024-11-16T21:31:57+00:00 weekly 0.7 https://trial.medpath.com/news/381d3800852d82a4/poster-shows-secukinumab-improves-hs-symptoms-and-psychiatric-comorbidities 2024-11-16T21:29:14+00:00 weekly 0.7 https://trial.medpath.com/news/02163cbc355cae71/bluejay-therapeutics-reports-best-in-class-monoclonal-antibody-bjt-778-achieved-100 2024-11-16T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/5c8af1c2bd05137a/killing-cancer-cells-with-alpha-particles-could-be-the-next-frontier-in-treatment-cbc-news 2024-11-16T21:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/73df6bec113cbf2f/abelzeta-s-novel-bispecific-car-t-therapy-shows-promise-for-autoimmune-diseases-in-preclinical-studies 2024-11-16T21:01:44+00:00 weekly 0.7 https://trial.medpath.com/news/2cfeb42cff73af3c/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-16T20:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/f4b33a6491eefbbc/osivax-announces-first-participant-vaccinated-in-phase-2a-clinical-booster-trial-of-influenza 2024-11-16T20:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/a4629003117f8fb7/gastrointestinal-disorders-and-aminotransferase-elevations-cited-as-most-noted-adverse 2024-11-16T20:04:58+00:00 weekly 0.7 https://trial.medpath.com/news/e8201f39548a2444/ozempic-wegovy-mounjaro-how-dangerous-are-they-the-herald 2024-11-16T20:01:03+00:00 weekly 0.7 https://trial.medpath.com/news/2e5e6180fa205df4/efficacy-of-the-preformulated-irrigation-solution-bactisure-r-in-acute-periprosthetic-joint-trials 2024-11-16T19:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/d22267bb294bb746/movano-focuses-on-eviemed-ring-fda-review-and-new-b2b-partnerships 2024-11-16T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/05f211294859e3b9/td-cowen-cuts-ascendis-pharma-target-to-153-keeps-buy-rating-investing-com-uk 2024-11-16T18:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/898b6876dcf23382/accuracy-of-healthcare-systems-data-for-identifying-cardiovascular-outcomes-after-stroke-due 2024-11-16T18:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/354d1dd0f277d11d/skye-bioscience-surpasses-50-patient-enrollment-in-cbeyond-phase-2-trial-of-pharmabiz 2024-11-16T18:28:16+00:00 weekly 0.7 https://trial.medpath.com/news/a81fb86b3a2f0bc3/new-alzheimer-s-drug-only-a-few-eligible-for-treatment-nl-times 2024-11-16T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/82919303bd0f29cb/crispr-gene-editing-therapy-shows-promise-as-cardiac-amyloidosis-treatment-in-early-study 2024-11-16T18:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/721d16d219e028c7/belantamab-mafodotin-triplet-improves-os-in-relapsed-refractory-myeloma 2024-11-16T18:02:18+00:00 weekly 0.7 https://trial.medpath.com/news/184741a4d72d8e01/expert-discusses-current-trials-in-bladder-cancer-to-watch-for-urology-times 2024-11-16T17:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/92164c0351ee39d7/intellia-s-crispr-therapy-shows-90-disease-protein-reduction-in-key-clinical-trial 2024-11-16T17:50:09+00:00 weekly 0.7 https://trial.medpath.com/news/826e14430082411b/usfda-approves-first-gene-therapy-for-treatment-of-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-16T17:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/0861463cbe6ff97e/alzheimer-s-research-accelerates-with-innovative-treatments-the-pinnacle-gazette 2024-11-16T16:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/c5352f98a459930f/biomarin-s-voxzogo-shows-remarkable-height-gains-in-452-child-achondroplasia-study 2024-11-16T16:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/7758a819c2666f92/aha-2024-unexplained-changes-in-cholesterol-could-help-identify-adults-at-risk-of-dementia 2024-11-16T16:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/7ac45d40b5b76969/idorsia-launches-aprocitentan-tryvio-in-us-for-treatment-of-hypertension-hcplive 2024-11-16T15:55:12+00:00 weekly 0.7 https://trial.medpath.com/news/00e435d341dcdeae/life-changing-alzheimer-s-drug-is-approved-for-use-to-reduce-cognitive-decline 2024-11-16T15:51:21+00:00 weekly 0.7 https://trial.medpath.com/news/38eeaeb721d726c9/medicus-pharma-makes-debut-on-nasdaq-raising-4m-to-advance-skin-cancer-trial-icymi 2024-11-16T15:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/39006b04c4230e97/intellia-announces-first-clinical-evidence-from-ongoing-globenewswire 2024-11-16T15:31:31+00:00 weekly 0.7 https://trial.medpath.com/news/e542557d6280fe10/ema-human-medicine-committee-recommends-approval-of-sanofi-s-sarclisa-to-treat-pharmabiz 2024-11-16T15:29:05+00:00 weekly 0.7 https://trial.medpath.com/news/3fc677eafceb2d49/navigating-a-sea-change-in-frontline-urothelial-carcinoma-treatment-onclive 2024-11-16T15:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/ae9fadfab2d2bae6/eli-lilly-s-tirzepatide-shows-38-drop-in-heart-failure-risk-major-weight-loss-in-trial 2024-11-16T15:18:15+00:00 weekly 0.7 https://trial.medpath.com/news/0bf50b9b119f349c/improving-disease-modification-and-immune-responses-in-myelofibrosis-with-pelabresib 2024-11-16T15:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/6a0062c978d93039/acepodia-announces-fda-clearance-of-investigational-new-drug-application-for-ace1831 2024-11-16T15:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/b2ad11c2435477fe/summit-tirzepatide-huge-win-for-hfpef-patients-with-obesity-tctmd-com 2024-11-16T15:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/a9fbbc0c58b93bb4/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-16T15:02:37+00:00 weekly 0.7 https://trial.medpath.com/news/16e88c4fdf48be33/nhs-to-launch-new-life-saving-cancer-trials-for-three-major-projects-gloucestershire-live 2024-11-16T14:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/9d7c0fec62d110d6/cytokinetics-presents-additional-data-from-galactic-hf-at-the-american-heart-morningstar 2024-11-16T14:43:50+00:00 weekly 0.7 https://trial.medpath.com/news/c608b88697a06af5/cabaletta-bio-reports-q3-2024-financial-results-and-clinical-trial-advancements 2024-11-16T14:28:33+00:00 weekly 0.7 https://trial.medpath.com/news/3079796b2ef758ad/innocare-announces-first-subject-dosed-in-the-phase-iii-registrational-trial-of-tyk2 2024-11-16T14:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/9f595ead871cc3f5/adicet-bio-s-adi-001-shows-breakthrough-car-t-cell-results-in-autoimmune-treatment-study 2024-11-16T14:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/f310d71a2309c702/cytokinetics-heart-failure-drug-shows-strong-efficacy-across-age-groups-in-phase-3-trial 2024-11-16T14:15:34+00:00 weekly 0.7 https://trial.medpath.com/news/ce81143277a59e9f/corin-receives-fda-510-k-clearance-of-icona-femoral-stem-healio 2024-11-16T14:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/50455e7121b16074/johnson-johnson-s-one-dose-covid-19-vaccine-gets-green-light-from-eu-regulator 2024-11-16T13:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/6f92e77beb794b66/greater-institutional-awareness-crucial-for-driving-biotechnology-adoption-csir 2024-11-16T13:59:30+00:00 weekly 0.7 https://trial.medpath.com/news/7f10938506dfb63c/junshi-biosciences-announces-uk-mhra-approval-for-marketing-of-toripalimab 2024-11-16T13:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/be1eabb731c242ef/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T13:41:13+00:00 weekly 0.7 https://trial.medpath.com/news/69744d43a7189db4/the-oncfive-top-oncology-articles-for-the-week-of-11-10-onclive 2024-11-16T13:02:22+00:00 weekly 0.7 https://trial.medpath.com/news/13f221bd28145151/plasma-progranulin-levels-are-correlated-with-left-ventricular-function-recovery-following 2024-11-16T12:28:54+00:00 weekly 0.7 https://trial.medpath.com/news/31968c9080efa6b9/chmp-recommends-first-line-pembrolizumab-plus-chemo-for-unresectable-non-onclive 2024-11-16T12:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/47b26ba034cb8f73/fda-clears-aria-detecting-software-nerivio-gains-expanded-indication-fda-approves 2024-11-16T12:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/4ce2e43ce56d0356/tetraspecific-b-nk-cell-better-than-t-cell-engagers-european-biotechnology-magazine 2024-11-16T12:01:28+00:00 weekly 0.7 https://trial.medpath.com/news/3db11641d5efe0c9/healthcare-providers-critical-for-diversifying-hbv-clinical-trial-recruitment-study-finds 2024-11-16T12:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/b3b8578802c5544c/christ-hospital-surgeons-perform-fourth-ever-implant-of-total-artificial-heart-wlwt 2024-11-16T11:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/2a3d8d558db48695/azurity-pharma-gets-us-fda-approval-for-danziten-tablets-the-first-and-only-nilotinib-with-no 2024-11-16T11:28:51+00:00 weekly 0.7 https://trial.medpath.com/news/abac8f55be70b595/promising-non-surgical-treatment-for-early-cataracts-insights-from-a-phase-ii-clinical-trial 2024-11-16T11:11:24+00:00 weekly 0.7 https://trial.medpath.com/news/ea8dc193f28e9ebb/ema-approves-the-third-dose-of-the-anti-covid-vaccine-telegrafi 2024-11-16T11:09:21+00:00 weekly 0.7 https://trial.medpath.com/news/3d73c5bbd00ca27e/chicago-northwestern-medicine-study-shows-severe-covid-19-may-shrink-cancer-cells 2024-11-16T11:00:50+00:00 weekly 0.7 https://trial.medpath.com/news/5ba5acda145c00ea/icometrix-s-ai-driven-mri-solution-icobrain-aria-receives-us-fda-clearance-for-safer 2024-11-16T10:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/bc1cce448ecbe854/usmani-projects-a-future-of-car-t-in-community-for-myeloma-and-other-cancers 2024-11-16T10:10:27+00:00 weekly 0.7 https://trial.medpath.com/news/b9a2d63cc1203b80/europe-approves-leqembi-for-alzheimer-s-treatment-the-pinnacle-gazette 2024-11-16T09:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/54de065529ff29a4/ema-announces-that-johnson-johnson-causes-rare-blood-clots-telegrafi 2024-11-16T09:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/e65ba5b0c87418ac/fda-approves-revumenib-in-kmt2a-rearranged-acute-leukemia-targeted-oncology 2024-11-16T09:22:00+00:00 weekly 0.7 https://trial.medpath.com/news/c3fa345ad6bd0410/inventiva-will-present-data-from-the-final-analysis-of-the-globenewswire 2024-11-16T09:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/25c3fedeecb76957/immutep-reports-positive-phase-ii-trial-results-investing-com-uk 2024-11-16T09:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/ea2cf95373538eef/cgtlive-r-s-weekly-rewind-november-15-2024 2024-11-16T08:21:16+00:00 weekly 0.7 https://trial.medpath.com/news/526a4413789c00f7/ema-committee-recommends-approval-of-eisai-biogen-s-lecanemab-to-treat-early 2024-11-16T07:28:15+00:00 weekly 0.7 https://trial.medpath.com/news/c3176e663e319158/merkel-germany-will-buy-russian-vaccines-if-it-receives-ema-approval-telegrafi 2024-11-16T07:27:46+00:00 weekly 0.7 https://trial.medpath.com/news/a316ba55992ca806/mek-inhibitor-scores-big-win-in-adults-children-with-neurofibromatosis-type-1 2024-11-16T07:19:42+00:00 weekly 0.7 https://trial.medpath.com/news/3a1afe022ecc5938/lack-of-data-on-the-vaccine-ema-postpones-the-approval-of-sputnik-v-telegrafi 2024-11-16T07:17:56+00:00 weekly 0.7 https://trial.medpath.com/news/c8e45686e6cce257/essential-malaria-drug-artemisinin-shows-signs-of-partial-resistance-in-children-contagion-live 2024-11-16T07:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/1a4bbd6bb6a46347/revumenib-elicits-favorable-efficacy-in-mnpm1-acute-myeloid-leukemia-cancer-network 2024-11-16T07:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/704606206a59812d/european-commission-grants-marketing-authorization-to-aflibercept-biosimilar-from-sandoz-group 2024-11-16T06:15:36+00:00 weekly 0.7 https://trial.medpath.com/news/8857f89b95d2a15b/a-multicenter-phase-ii-trial-of-triplet-antiemetic-therapy-with-palonosetron-aprepitant-and-nature 2024-11-16T06:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/261070c3139edd39/noam-solomon-bringing-the-human-story-to-ai-pharmaceutical-executive 2024-11-16T05:41:16+00:00 weekly 0.7 https://trial.medpath.com/news/f308299f0018bcfa/vtp-300-nivolumab-combination-shows-promise-for-functional-hbv-cure-in-phase-2b-trial 2024-11-16T05:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/8eb6dd23eadb671b/airway-on-a-chip-could-speed-up-future-drug-and-therapy-development-prweb 2024-11-16T05:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/16782fa7d681b6d8/ema-s-chmp-finds-path-to-leqembi-nod-backs-three-other-new-drugs-biocentury 2024-11-16T04:52:59+00:00 weekly 0.7 https://trial.medpath.com/news/1f22d8dd00310a04/spirovant-sciences-doses-first-subject-in-cystic-fibrosis-gene-therapy-trial 2024-11-16T04:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/000c3097e7194531/boston-pharmaceuticals-to-announce-positive-phase-2-data-on-efimosfermin-alfa-bos-580 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/3b64ab9252cfd7f5/arbutus-and-barinthus-bio-announce-new-data-from-the-im-prove-ii-trial-showing-that-the 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/ee10c381cdef9e9b/os-therapies-reports-third-quarter-2024-financial-results-and-provides-business-update 2024-11-16T04:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/cd1d35bb4865063c/cofactor-genomics-expands-clinical-use-of-oncoprism-as-their-ai-enabled-rna-test 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/f9da65b67c6817eb/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-biospace 2024-11-16T04:20:06+00:00 weekly 0.7 https://trial.medpath.com/news/96a825047b7b15f0/eyenovia-provides-update-on-phase-3-chaperone-study-biospace 2024-11-16T04:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/2f56cd0e51bed608/immutep-s-lag-3-adds-to-keytruda-in-first-line-lung-cancer-citeline-news-insights 2024-11-16T04:19:43+00:00 weekly 0.7 https://trial.medpath.com/news/f4456dac910116a3/managing-dual-checkpoint-inhibition-side-effects-in-nsclc-expert-insights-on-treatment-strategies 2024-11-16T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/733a82cf58de09f7/immutep-reports-positive-phase-ii-trial-results-by-investing-com 2024-11-16T03:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/e6be155a8552bc4e/adverum-biotechnologies-announces-webcast-to-report-52-week-luna-phase-2-clinical 2024-11-16T02:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/c6f62f60dc696a52/precede-biosciences-presents-new-data-at-aacr-lbx-2024-globenewswire 2024-11-16T02:31:28+00:00 weekly 0.7 https://trial.medpath.com/news/efb95ceb5951449a/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/c08623c420769a99/precede-biosciences-presents-new-data-at-aacr-lbx-2024-demonstrating-an-accurate 2024-11-16T02:21:14+00:00 weekly 0.7 https://trial.medpath.com/news/b66845f500969aec/life-changing-alzheimer-s-drug-approved-for-use-in-eu-to-reduce-cognitive-decline 2024-11-16T02:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/afd467ff8922fcc4/eu-approves-life-changing-important-alzheimer-s-drug-which-can-drastically-slow-onset-surrey-live 2024-11-16T02:11:23+00:00 weekly 0.7 https://trial.medpath.com/news/691eae1ebaf449f8/immutep-reports-promising-phase-ii-sarcoma-trial-results-markets-insider 2024-11-16T02:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/5fdd3ce8d2e94f57/fully-loaded-secondary-prevention-studies-of-lecanemab-donanemab-alzforum 2024-11-16T01:21:02+00:00 weekly 0.7 https://trial.medpath.com/news/356ec11935da489d/ema-committee-recommends-repotrectinib-for-lung-cancer-by-investing-com 2024-11-16T01:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/a97518dac37b0584/invivyd-reports-clinical-efficacy-data-from-canopy-phase-3-trial-of-pemivibart 2024-11-16T00:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/5b2401a0a5897780/vir-biotechnology-reports-positive-end-of-treatment-data-from-march-study 2024-11-16T00:14:51+00:00 weekly 0.7 https://trial.medpath.com/news/03ec6bb08805787b/protara-therapeutics-inc-to-present-new-interim-data-from-phase-2-advanced-2-trial-of 2024-11-16T00:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/495e00898ed6b1ab/sol-gel-reports-third-quarter-2024-financial-results-and-provides-corporate-updates 2024-11-16T00:02:56+00:00 weekly 0.7 https://trial.medpath.com/news/9100509bfd0ccfdf/nih-funding-opportunities-november-2024-university-of-utah-health 2024-11-16T00:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/44ab62e852b19da9/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/2fd6ef67732adebd/ideaya-biosciences-inc-idya-bcg-matrix-analysis-2024 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/517455f7b4cb1aab/ideaya-biosciences-inc-idya-bcg-matrix-analysis 2024-11-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/c669365564d1eb51/gohibic-for-sars-cov-2-induced-ards-among-eight-new-drugs-to-win-ema-nod 2024-11-15T23:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/efa5b3df034ca0a8/pearl-study-compares-first-line-durvalumab-monotherapy-with-chemotherapy-in 2024-11-15T23:27:47+00:00 weekly 0.7 https://trial.medpath.com/news/22056aa47322fdab/fda-approves-first-menin-inhibitor-for-acute-leukemia-medpage-today 2024-11-15T23:15:46+00:00 weekly 0.7 https://trial.medpath.com/news/92ed1178b147bac4/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-markets-data 2024-11-15T23:11:12+00:00 weekly 0.7 https://trial.medpath.com/news/562c3d420192ec71/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-morningstar 2024-11-15T22:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/354beb23d28d8c5b/syndax-s-revuforj-wins-fda-approval-as-first-menin-inhibitor-for-acute-leukemia-sndx 2024-11-15T22:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/78c6eacab8137c86/zevra-therapeutics-strong-financials-strategic-fda-approval-and-growth-prospects-drive 2024-11-15T22:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/2a60ee2c46a53427/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin 2024-11-15T22:39:49+00:00 weekly 0.7 https://trial.medpath.com/news/fcfbc275626ba248/syndax-announces-fda-approval-of-revuforj-r-revumenib-the-first-and-only-menin-placera 2024-11-15T22:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/dbe057c277d343d1/alpha-cognition-s-fda-approved-alzheimer-s-drug-zunveyl-set-for-2025-launch 2024-11-15T22:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/f84db5fdfbfa47f2/medicus-pharma-completes-4m-ipo-for-skin-cancer-treatment-development-mdcx-stock-news 2024-11-15T21:55:26+00:00 weekly 0.7 https://trial.medpath.com/news/23f3dcecac0619f9/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation 2024-11-15T21:53:21+00:00 weekly 0.7 https://trial.medpath.com/news/6a646a507e334fa7/fda-approves-revumenib-for-the-treatment-of-relapsed-or-refractory-acute-leukemia 2024-11-15T21:50:42+00:00 weekly 0.7 https://trial.medpath.com/news/8c50153914aac53c/fda-approves-revuforj-for-relapsed-refractory-acute-leukemia-subset-cure-today 2024-11-15T21:44:50+00:00 weekly 0.7 https://trial.medpath.com/news/a84f8506894fedf0/study-finds-no-birth-defect-risk-from-tetracycline-use-during-first-trimester-of-pregnancy 2024-11-15T21:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/0ec253ce2ccbe282/fda-approves-revumenib-for-relapsed-refractory-kmt2a-translocated-acute-leukemia 2024-11-15T21:35:43+00:00 weekly 0.7 https://trial.medpath.com/news/917e8a8ddd23a753/fda-approves-revumenib-for-r-r-acute-leukemia-with-a-kmt2a-translocation-onclive 2024-11-15T21:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/e83655843806716d/positive-ema-reversal-boosts-biogen-s-leqembi-prospects-despite-challenges 2024-11-15T21:27:02+00:00 weekly 0.7 https://trial.medpath.com/news/793a8ea763ca886c/fda-approves-first-aadc-deficiency-treatment-scientist-live 2024-11-15T21:22:26+00:00 weekly 0.7 https://trial.medpath.com/news/5ee54443b469cc90/eisai-wins-on-appeal-chmp-recommends-leqembi-for-alzheimer-s-bioworld 2024-11-15T20:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/98abeba622b3c12f/filament-health-revenue-slides-94-as-cash-reserves-dwindle-green-market-report 2024-11-15T20:17:38+00:00 weekly 0.7 https://trial.medpath.com/news/e0736c286b7f3db4/european-agency-signals-approval-for-keytruda-for-first-line-mesothelioma-treatment 2024-11-15T20:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/349d3b4578bcf426/the-joy-of-witnessing-science-transform-a-life-research-horizons 2024-11-15T20:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/587ca137ae273828/fda-oks-ninlotinib-tablets-with-no-mealtime-restrictions-for-cml-oncology-nursing-news 2024-11-15T20:10:19+00:00 weekly 0.7 https://trial.medpath.com/news/111eacf808d279fe/outcomes-of-contemporary-therapy-for-cardiogenic-shock-due-to-severe-aortic-stenosis 2024-11-15T20:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/f3fe25a93b81696b/repotrectinib-garners-positive-chmp-opinion-for-ros1-nsclc-and-ntrk-solid-tumors 2024-11-15T20:06:01+00:00 weekly 0.7 https://trial.medpath.com/news/88fa8194cbcef1df/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy 2024-11-15T20:03:02+00:00 weekly 0.7 https://trial.medpath.com/news/208aba53ebb2b3f3/fda-accepts-sbla-review-for-dupilumab-in-treatment-of-csu-in-adult-and-pediatric-patients 2024-11-15T19:59:22+00:00 weekly 0.7 https://trial.medpath.com/news/4810987427ab8518/nerivio-ren-wearable-now-fda-cleared-to-treat-migraines-in-children-8-years-and-up 2024-11-15T19:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/abb126378e04c463/fda-approves-nilotinib-with-no-mealtime-restrictions-in-ph-positive-cml 2024-11-15T19:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/36ee413e96382d20/formycon-ag-de000a1ewvy8-ad-hoc-news-de 2024-11-15T19:37:52+00:00 weekly 0.7 https://trial.medpath.com/news/f933b7c8458dc783/plx-self-sustaining-rise-to-lead-in-renal-rare-disease-zacks-small-cap-research 2024-11-15T19:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/e3d7ae08b1e61993/ascendis-pharma-reports-third-quarter-2024-financial-results-yahoo-finance 2024-11-15T19:21:49+00:00 weekly 0.7 https://trial.medpath.com/news/d3a073753f825d4d/with-phase-iii-myopia-termination-eyenovia-open-to-all-strategic-options-citeline 2024-11-15T19:16:26+00:00 weekly 0.7 https://trial.medpath.com/news/87ba4feb63da40f6/tamil-nadu-launches-phase-ii-of-uttasathai-uruthi-sei-scheme-to-support-pregnant-women 2024-11-15T19:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/89a70765844aaef0/sandoz-receives-european-commission-approval-for-afqlir-r-aflibercept-further-biospace 2024-11-15T19:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/02a8b4d5c4614a34/dupixent-r-dupilumab-sbla-accepted-for-fda-review-for-the-treatment-of-chronic-biospace 2024-11-15T19:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/fb1bce356f1d87a7/granite-plus-icis-and-bevacizumab-chemo-shows-improved-pfs-trend-in-mss-mcrc 2024-11-15T19:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/ed66eb44d9e23dc1/nmo-drug-looks-good-for-igg4-related-disease-medpage-today 2024-11-15T19:05:16+00:00 weekly 0.7 https://trial.medpath.com/news/367170abf300cab1/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday-benzinga 2024-11-15T18:47:23+00:00 weekly 0.7 https://trial.medpath.com/news/652d4097ffa58cf6/what-s-going-on-with-liver-disease-focused-vir-biotechnology-stock-is-friday 2024-11-15T18:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/2d64fab804d45546/european-medicines-agency-reverses-opinion-on-lecanemab-for-alzheimer-disease-but 2024-11-15T18:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/61388b0a31b30acd/fda-accepts-resubmission-of-supplemental-biologics-license-application-for-dupixent-for 2024-11-15T18:41:30+00:00 weekly 0.7 https://trial.medpath.com/news/0d72152ae0c032d6/zevra-testing-beta-blocker-celiprolol-for-veds-in-phase-3-us-study-ehlers-danlos-news 2024-11-15T18:37:41+00:00 weekly 0.7 https://trial.medpath.com/news/da2dea1e3bad11f8/anda-approvals-new-drug-applications-and-505-b-2-applications-third-quarter 2024-11-15T18:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/30e966d0933e9292/hope-on-the-horizon-nephrologists-emphasize-need-for-innovative-c3g-treatments-as 2024-11-15T18:32:32+00:00 weekly 0.7 https://trial.medpath.com/news/04f2e9b6ec822138/how-a-biogen-drug-set-the-stage-for-a-new-biotech-targeting-als-biopharma-dive 2024-11-15T18:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/59d748a5c374c020/fda-approves-new-class-of-hemophilia-treatment-coagulation-disorders-jama-network 2024-11-15T18:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/61eab85ae38ccc34/efficacy-of-attractive-targeted-sugar-bait-stations-against-malaria-in-western-province-zambia 2024-11-15T18:20:33+00:00 weekly 0.7 https://trial.medpath.com/news/cbcfe230bd6e42db/allogene-s-car-t-allo-316-demonstrates-ability-to-produce-responses-in-renal-cell 2024-11-15T18:18:36+00:00 weekly 0.7 https://trial.medpath.com/news/4fa09fac44a28570/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T18:15:59+00:00 weekly 0.7 https://trial.medpath.com/news/8981b04c6a61575e/study-launches-of-qxl138am-in-multiple-myeloma-and-solid-tumors-targeted-oncology 2024-11-15T18:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/329e7f9fffcc5909/fda-approves-danziten-for-leukemia-subset-that-does-not-require-fasting-cure-today 2024-11-15T18:04:48+00:00 weekly 0.7 https://trial.medpath.com/news/0b35a2ddbb1957b0/sandoz-receives-european-commission-approval-for-afqlir-r-globenewswire 2024-11-15T18:01:40+00:00 weekly 0.7 https://trial.medpath.com/news/9fc3f6e429474d96/fda-reviews-sanofi-and-regeneron-s-dupixent-label-expansion-for-urticaria 2024-11-15T17:45:53+00:00 weekly 0.7 https://trial.medpath.com/news/324e139e48eb1c59/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety 2024-11-15T17:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/27aadef16a1284d5/why-the-ema-said-no-to-kizfizo-and-cinainu 2024-11-15T17:36:09+00:00 weekly 0.7 https://trial.medpath.com/news/c899efa6056564a7/two-year-phase-iii-data-confirm-long-term-efficacy-safety-of-bimzelx-in-psoriatic-arthritis 2024-11-15T17:28:35+00:00 weekly 0.7 https://trial.medpath.com/news/368c519db41916af/vir-biotechnology-inc-announces-positive-end-of-t-treatment-results-for-tobevibart-and 2024-11-15T17:25:07+00:00 weekly 0.7 https://trial.medpath.com/news/5efb44e309d19624/european-commission-grants-marketing-authorization-to-biosimilar-from-sandoz-group 2024-11-15T17:24:55+00:00 weekly 0.7 https://trial.medpath.com/news/147f4809f0609d9d/aflibercept-biosimilar-fyb203-ahzantive-r-baiama-r-receives-positive-chmp-opinion-from-ema 2024-11-15T17:24:03+00:00 weekly 0.7 https://trial.medpath.com/news/8d8bdbd7ca2b4658/positive-chmp-opinion-for-formycon-s-aflibercept-biosimilar-fyb203-webdisclosure 2024-11-15T17:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/453f574e770223ea/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/89c67d30189a479b/isatuximab-plus-vrd-earns-chmp-recommendation-for-newly-diagnosed-transplant 2024-11-15T17:12:17+00:00 weekly 0.7 https://trial.medpath.com/news/0bf84db08cabfc3c/iqirvo-r-elafibranor-data-shows-efficacy-and-safety-for-up-to-3-years-in-patients-with-pbc-ipsen 2024-11-15T17:09:26+00:00 weekly 0.7 https://trial.medpath.com/news/b73d176253b6ac69/fda-approves-l-amino-acid-decarboxylase-deficiency-gene-therapy-nature 2024-11-15T17:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/51fee18a497563e9/pembrolizumab-chemo-earns-positive-eu-chmp-opinion-in-mesothelioma 2024-11-15T17:07:04+00:00 weekly 0.7 https://trial.medpath.com/news/07804eaee2e3bc0a/european-watchdog-partially-approves-new-alzheimer-s-drug-macau-business 2024-11-15T17:05:35+00:00 weekly 0.7 https://trial.medpath.com/news/522bb94c7a5373ca/neoadjuvant-chemoradiation-followed-by-immunochemotherapy-and-surgery-may-improve 2024-11-15T17:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/4ba0e6f44de6c528/drugs-like-ozempic-may-help-lower-2nd-stroke-heart-attack-risk 2024-11-15T17:02:49+00:00 weekly 0.7 https://trial.medpath.com/news/765b3c22d2d9ed92/new-research-sheds-light-on-a-surprising-connection-between-covid-19-and-cancer-regression 2024-11-15T17:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/72ffe226702b61c9/pipeline-watch-four-approvals-and-10-phase-iii-readouts-citeline 2024-11-15T16:56:10+00:00 weekly 0.7 https://trial.medpath.com/news/8ec84f0bd52e055b/immunotherapy-combination-for-cutaneous-melanoma-the-asco-post 2024-11-15T16:54:52+00:00 weekly 0.7 https://trial.medpath.com/news/434f8fef811e111b/ac-immune-s-stock-jumps-after-parkinson-s-therapy-shows-signs-of-benefit 2024-11-15T16:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/98047093188154cb/tivic-hits-enrolment-target-for-vagus-nerve-stimulation-trial 2024-11-15T16:51:37+00:00 weekly 0.7 https://trial.medpath.com/news/ab16c38bfb948979/chmp-recommends-approval-of-nivolumab-ipilimumab-in-msi-h-dmmr-mcrc-onclive 2024-11-15T16:51:20+00:00 weekly 0.7 https://trial.medpath.com/news/0c01d2998a3c2029/an-update-on-therapeutics-for-covid-19-medpage-today 2024-11-15T16:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/86adad09d014df55/research-study-explores-targeted-therapy-for-recurrent-high-grade-glioma 2024-11-15T16:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/a044e5baad28d65c/fda-accepts-application-for-dupilumab-to-treat-chronic-spontaneous-urticaria 2024-11-15T16:31:30+00:00 weekly 0.7 https://trial.medpath.com/news/c3e0ecabf8f9aaec/fda-grants-new-nilotinib-formulation-approval-to-treat-adults-with-chronic-myeloid-leukemia 2024-11-15T16:31:12+00:00 weekly 0.7 https://trial.medpath.com/news/2438a0ad07737d48/bristol-myers-gets-positive-ema-opinion-for-repotrectinib-nyse-bmy-seeking-alpha 2024-11-15T16:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/f2593f94d7b126ab/ptc-therapeutics-gene-therapy-kebilidi-to-treat-aadc-deficiency-receives-us-fda-approval 2024-11-15T16:28:40+00:00 weekly 0.7 https://trial.medpath.com/news/e9805c82b89c1e23/fda-approves-ptc-therapeutics-kebillidi-for-aromatic-l-amino-acid-decarboxylase-deficiency 2024-11-15T16:26:15+00:00 weekly 0.7 https://trial.medpath.com/news/d61cd2ce25b4e7d7/vir-bio-s-hepatitis-b-treatment-shows-46-success-rate-in-key-clinical-trial-stock-titan 2024-11-15T16:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/248a0f1dcc856971/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-marketscreener 2024-11-15T16:25:23+00:00 weekly 0.7 https://trial.medpath.com/news/d9e7155f951c36d1/eyenovia-shares-plummet-70-after-it-drops-lead-program-biospace 2024-11-15T16:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/71c092cbe40cbbdb/vir-biotechnology-announces-positive-end-of-treatment-results-for-tobevibart-and-markets-data 2024-11-15T16:21:29+00:00 weekly 0.7 https://trial.medpath.com/news/d6506d17c45206fc/promising-hepatitis-b-treatment-data-presented-by-vir-biotechnology-investing-com 2024-11-15T16:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/e50e92acf10c3d7e/parkinson-immunotherapy-aci-7104-056-demonstrates-positive-antibody-responses-in 2024-11-15T16:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/2c0f613f096eccac/improvements-to-children-s-surgery-to-be-identified-with-the-help-of-the-nhs-digitrials 2024-11-15T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/cc8bbddf9bce4688/barinthus-bio-announces-results-from-ongoing-phase-2b-globenewswire 2024-11-15T16:07:55+00:00 weekly 0.7 https://trial.medpath.com/news/43fa62fb7e84c5b8/fda-grants-rare-pediatric-designation-to-elraglusib-for-ewing-sarcoma-oncology-nursing-news 2024-11-15T16:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/c2f2faec2f1b4928/in-brief-rtw-biotech-notes-drug-approval-in-china-for-investee-corxel-shares-magazine 2024-11-15T16:05:09+00:00 weekly 0.7